Document:

EX-10.1

 Exhibit 10.1 

SURFACE ONCOLOGY, INC. 

2014 STOCK OPTION AND GRANT PLAN 
 SECTION
1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS 
 The name of the plan is the Surface Oncology, Inc. 2014 Stock Option and Grant Plan
(the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Surface Oncology, Inc., a Delaware corporation (including any successor entity, the
“Company”) and its Subsidiaries, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a proprietary interest in the Company. 

The following terms shall be defined as set forth below: 

“Affiliate” of any Person means a Person that directly or indirectly, through one or more intermediaries, controls, is
controlled by or is under common control with the first mentioned Person. A Person shall be deemed to control another Person if such first Person possesses directly or indirectly the power to direct, or cause the direction of, the management and
policies of the second Person, whether through the ownership of voting securities, by contract or otherwise. 
 “Award” or
“Awards,” except where referring to a particular category of grant under the Plan, shall include Incentive Stock Options, Non-Qualified Stock Options, Restricted Stock Awards, Unrestricted
Stock Awards, Restricted Stock Units or any combination of the foregoing. 
 “Award Agreement” means a written or
electronic agreement setting forth the terms and provisions applicable to an Award granted under the Plan. Each Award Agreement may contain terms and conditions in addition to those set forth in the Plan; provided, however, in the event of
any conflict in the terms of the Plan and the Award Agreement, the terms of the Plan shall govern. 
 “Board” means
the Board of Directors of the Company. 
 “Cause” shall have the meaning as set forth in the Award Agreement(s). In the
case that any Award Agreement does not contain a definition of “Cause,” it shall mean (i) the grantee’s dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective
customers, suppliers vendors or other third parties with which such entity does business; (ii) the grantee’s commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the
grantee’s failure to perform his assigned duties and responsibilities to the reasonable satisfaction of the Company which failure continues, in the reasonable judgment of the Company, after written notice given to the grantee by the Company;
(iv) the grantee’s gross negligence, willful misconduct or insubordination with respect to the Company or any Affiliate of the Company; or (v) the grantee’s material violation of any provision of any agreement(s) between the
grantee and the Company relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions. 

  

 “Chief Executive Officer” means the Chief Executive Officer of the Company or,
if there is no Chief Executive Officer, then the President of the Company. 
 “Code” means the Internal Revenue Code
of 1986, as amended, and any successor Code, and related rules, regulations and interpretations. 
 “Committee”
means the Committee of the Board referred to in Section 2. 
 “Consultant” means any natural person that provides bona
fide services to the Company (including a Subsidiary), and such services are not in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the
Company’s securities. 
 “Disability” means “disability” as defined in Section 422(c) of the Code. 

“Effective Date” means the date on which the Plan is adopted as set forth on the final page of the Plan. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. 

“Fair Market Value” of the Stock on any given date means the fair market value of the Stock determined in good faith by the
Committee based on the reasonable application of a reasonable valuation method not inconsistent with Section 409A of the Code. If the Stock is admitted to trade on a national securities exchange, the determination shall be made by reference to
the closing price reported on such exchange. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price. If the date for which Fair Market Value is
determined is the first day when trading prices for the Stock are reported on a national securities exchange, the Fair Market Value shall be the “Price to the Public” (or equivalent) set forth on the cover page for the final prospectus
relating to the Company’s Initial Public Offering. 
 “Good Reason” shall have the meaning as set forth in the Award
Agreement(s). In the case that any Award Agreement does not contain a definition of “Good Reason,” it shall mean (i) a material diminution in the grantee’s base salary except for across-the-board salary reductions similarly
affecting all or substantially all similarly situated employees of the Company or (ii) a change of more than 50 miles in the geographic location at which the grantee provides services to the Company, so long as the grantee provides at least 90
days notice to the Company following the initial occurrence of any such event and the Company fails to cure such event within 30 days thereafter. 

“Grant Date” means the date that the Committee designates in its approval of an Award in accordance with applicable law as
the date on which the Award is granted, which date may not precede the date of such Committee approval. 
 “Holder” means,
with respect to an Award or any Shares, the Person holding such Award or Shares, including the initial recipient of the Award or any Permitted Transferee. 

  
 2 

 “Incentive Stock Option” means any Stock Option designated and qualified as an
“incentive stock option” as defined in Section 422 of the Code. 
 “Initial Public Offering” means the
consummation of the first firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act covering the offer and sale by the Company of its equity securities, as a result of or following which
the Stock shall be publicly held. 
 “Non-Qualified Stock Option” means any Stock Option that is not an Incentive Stock
Option. 
 “Option” or “Stock Option” means any option to purchase shares of Stock granted pursuant to
Section 5. 
 “Permitted Transferees” shall mean any of the following to whom a Holder may transfer Shares hereunder
(as set forth in Section 9(a)(ii)(A)): the Holder’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or
sister-in-law, including adoptive relationships, any person sharing the Holder’s household (other than a tenant or employee), a trust in which these persons have more than fifty percent of the beneficial interest, a foundation in which these
persons control the management of assets, and any other entity in which these persons own more than fifty percent of the voting interests; provided, however, that any such trust does not require or permit distribution of any Shares during the
term of the Award Agreement unless subject to its terms. Upon the death of the Holder, the term Permitted Transferees shall also include such deceased Holder’s estate, executors, administrators, personal representatives, heirs, legatees and
distributees, as the case may be. 
 “Person” shall mean any individual, corporation, partnership (limited or general),
limited liability company, limited liability partnership, association, trust, joint venture, unincorporated organization or any similar entity. 

“Restricted Stock Award” means Awards granted pursuant to Section 6 and “Restricted Stock” means Shares
issued pursuant to such Awards. 
 “Restricted Stock Unit” means an Award of phantom stock units to a grantee, which may be
settled in cash or Shares as determined by the Committee, pursuant to Section 8. 
 “Sale Event” means the consummation of
(i) the dissolution or liquidation of the Company, (ii) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (iii) a merger, reorganization or consolidation
pursuant to which the holders of the Company’s outstanding voting power immediately prior to such transaction do not own a majority of the outstanding voting power of the surviving or resulting entity (or its ultimate parent, if applicable),
(iv) the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of related transactions by a Person or group of Persons, or (v) any other acquisition of the business of the
Company, as determined by the Board; provided, however, that the Company’s Initial Public Offering, any subsequent public offering or another capital raising event, or a merger effected solely to change the Company’s domicile shall
not constitute a “Sale Event.” 

  
 3 

 “Section 409A” means Section 409A of the Code and the regulations and other
guidance promulgated thereunder. 
 “Securities Act” means the Securities Act of 1933, as amended, and the rules and
regulations thereunder. 
 “Service Relationship” means any relationship as a full-time employee, part-time employee,
director or other key person (including Consultants) of the Company or any Subsidiary or any successor entity (e.g., a Service Relationship shall be deemed to continue without interruption in the event an individual’s status changes from
full-time employee to part-time employee or Consultant). 
 “Shares” means shares of Stock. 

“Stock” means the Common Stock, par value $0.0001 per share, of the Company. 

“Subsidiary” means any corporation or other entity (other than the Company) in which the Company has more than a 50
percent interest, either directly or indirectly. 
 “Ten Percent Owner” means an employee who owns or is deemed to
own (by reason of the attribution rules of Section 424(d) of the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent of the Company or any Subsidiary.  

“Termination Event” means the termination of the Award recipient’s Service Relationship with the Company and its
Subsidiaries for any reason whatsoever, regardless of the circumstances thereof, and including, without limitation, upon death, disability, retirement, discharge or resignation for any reason, whether voluntarily or involuntarily. The following
shall not constitute a Termination Event: (i) a transfer to the service of the Company from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another Subsidiary or (ii) an approved leave of absence for military
service or sickness, or for any other purpose approved by the Committee, if the individual’s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if
the Committee otherwise so provides in writing. 
 “Unrestricted Stock Award” means any Award granted pursuant to
Section 7 and “Unrestricted Stock” means Shares issued pursuant to such Awards. 

SECTION 2. ADMINISTRATION OF PLAN; COMMITTEE AUTHORITY TO SELECT GRANTEES AND DETERMINE 
AWARDS 
 (a) Administration of Plan. The Plan shall be administered by the Board, or at the discretion of the Board, by a
committee of the Board, comprised of not less than two directors. All references herein to the “Committee” shall be deemed to refer to the group then responsible for administration of the Plan at the relevant time (i.e., either the Board
of Directors or a committee or committees of the Board, as applicable). 
 (b) Powers of Committee. The Committee shall have the power
and authority to grant Awards consistent with the terms of the Plan, including the power and authority: 

  
 4 

 (i) to select the individuals to whom Awards may from time to time be granted; 

(ii) to determine the time or times of grant, and the amount, if any, of Incentive Stock Options,
Non-Qualified Stock Options, Restricted Stock Awards, Unrestricted Stock Awards, Restricted Stock Units, or any combination of the foregoing, granted to any one or more grantees; 

(iii) to determine the number of Shares to be covered by any Award and, subject to the provisions of the Plan, the price, exercise price,
conversion ratio or other price relating thereto; 
 (iv) to determine and, subject to Section 12, to modify from time to time the terms
and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the form of Award Agreements; 

(v) to accelerate at any time the exercisability or vesting of all or any portion of any Award; 

(vi) to impose any limitations on Awards, including limitations on transfers, repurchase provisions and the like, and to exercise repurchase
rights or obligations; 
 (vii) subject to Section 5(a)(ii) and any restrictions imposed by Section 409A, to extend at any time the
period in which Stock Options may be exercised; and 
 (viii) at any time to adopt, alter and repeal such rules, guidelines and practices for
administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including Award Agreements); to make all determinations it deems advisable for the
administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan. 
 All
decisions and interpretations of the Committee shall be binding on all persons, including the Company and all Holders. 
 (c) Award
Agreement. Awards under the Plan shall be evidenced by Award Agreements that set forth the terms, conditions and limitations for each Award. 

(d) Indemnification. Neither the Board nor the Committee, nor any member of either or any delegate thereof, shall be liable for any act,
omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Committee (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by
the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys’ fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company’s governing documents,
including its certificate of incorporation or bylaws, or any directors’ and officers’ liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company. 

  
 5 

 (e) Foreign Award Recipients. Notwithstanding any provision of the Plan to the contrary,
in order to comply with the laws in other countries in which the Company and any Subsidiary operate or have employees or other individuals eligible for Awards, the Committee, in its sole discretion, shall have the power and authority to:
(i) determine which Subsidiaries, if any, shall be covered by the Plan; (ii) determine which individuals, if any, outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award
granted to individuals outside the United States to comply with applicable foreign laws; (iv) establish subplans and modify exercise procedures and other terms and procedures, to the extent the Committee determines such actions to be necessary
or advisable (and such subplans and/or modifications shall be attached to the Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitation contained in Section 3(a) hereof;
and (v) take any action, before or after an Award is made, that the Committee determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. 

SECTION 3. STOCK ISSUABLE UNDER THE PLAN; MERGERS AND OTHER TRANSACTIONS; SUBSTITUTION 

(a) Stock Issuable. The maximum number of Shares reserved and available for issuance under the Plan shall be 3,354,117 Shares, subject
to adjustment as provided in Section 3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise
terminated (other than by exercise) and Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall be added back to the Shares available for issuance under the Plan. Subject to
such overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award, and no more than 33,541,170 Shares may be issued pursuant to Incentive Stock Options. The Shares available for issuance under the Plan
may be authorized but unissued Shares or Shares reacquired by the Company. Beginning on the date that the Company becomes subject to Section 162(m) of the Code, Options with respect to no more than 3,354,117 Shares shall be granted to any one
individual in any calendar year period. 
 (b) Changes in Stock. Subject to Section 3(c) hereof, if, as a result of any
reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company’s capital stock, the outstanding Shares are increased or decreased or are exchanged for a different
number or kind of shares or other securities of the Company, or additional Shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such Shares or other securities, in each case,
without the receipt of consideration by the Company, or, if, as a result of any merger or consolidation, or sale of all or substantially all of the assets of the Company, the outstanding Shares are converted into or exchanged for other securities of
the Company or any successor entity (or a parent or subsidiary thereof), the Committee shall make an appropriate and proportionate adjustment in (i) the maximum number of Shares reserved for issuance under the Plan, (ii) the number and
kind of Shares or other securities subject to any then outstanding 

  
 6 

 
Awards under the Plan, (iii) the repurchase price, if any, per Share subject to each outstanding Award, and (iv) the exercise price for each Share subject to any then outstanding Stock
Options under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of Stock Options) as to which such Stock Options remain exercisable. The Committee shall in any event make such adjustments as
may be required by Section 25102(o) of the California Corporation Code and the rules and regulations promulgated thereunder. The adjustment by the Committee shall be final, binding and conclusive. No fractional Shares shall be issued under the
Plan resulting from any such adjustment, but the Committee in its discretion may make a cash payment in lieu of fractional shares. 
 (c)
Sale Events. 
 (i) Options. 

(A) In the case of and subject to the consummation of a Sale Event, the Plan and all outstanding Options issued hereunder shall
terminate upon the effective time of any such Sale Event unless assumed or continued by the successor entity, or new stock options or other awards of the successor entity or parent thereof are substituted therefor, with an equitable or proportionate
adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree (after taking into account any acceleration hereunder and/or pursuant to the terms of any Award Agreement). 

(B) In the event of the termination of the Plan and all outstanding Options issued hereunder pursuant to Section 3(c),
each Holder of Options shall be permitted, within a period of time prior to the consummation of the Sale Event as specified by the Committee, to exercise all such Options which are then exercisable or will become exercisable as of the effective time
of the Sale Event; provided, however, that the exercise of Options not exercisable prior to the Sale Event shall be subject to the consummation of the Sale Event. 

(C) Notwithstanding anything to the contrary in Section 3(c)(i)(A), in the event of a Sale Event, the Company shall have
the right, but not the obligation, to make or provide for a cash payment to the Holders of Options, without any consent of the Holders, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the value as
determined by the Committee of the consideration payable per share of Stock pursuant to the Sale Event (the “Sale Price”) times the number of Shares subject to outstanding Options being cancelled (to the extent then vested and exercisable,
including by reason of acceleration in connection with such Sale Event, at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding vested and exercisable Options. 

  
 7 

 (ii) Restricted Stock and Restricted Stock Unit Awards. 

(A) In the case of and subject to the consummation of a Sale Event, all unvested Restricted Stock and unvested Restricted Stock
Unit Awards (other than those becoming vested as a result of the Sale Event) issued hereunder shall be forfeited immediately prior to the effective time of any such Sale Event unless assumed or continued by the successor entity, or awards of the
successor entity or parent thereof are substituted therefor, with an equitable or proportionate adjustment as to the number and kind of shares subject to such awards as such parties shall agree (after taking into account any acceleration hereunder
and/or pursuant to the terms of any Award Agreement). 
 (B) In the event of the forfeiture of Restricted Stock pursuant to
Section 3(c)(ii)(A), such Restricted Stock shall be repurchased from the Holder thereof at a price per share equal to the original per share purchase price paid by the Holder (subject to adjustment as provided in Section 3(b)) for such
Shares. 
 (C) Notwithstanding anything to the contrary in Section 3(c)(ii)(A), in the event of a Sale Event, the
Company shall have the right, but not the obligation, to make or provide for a cash payment to the Holders of Restricted Stock or Restricted Stock Unit Awards, without consent of the Holders, in exchange for the cancellation thereof, in an amount
equal to the Sale Price times the number of Shares subject to such Awards, to be paid at the time of such Sale Event or upon the later vesting of such Awards. 

SECTION 4. ELIGIBILITY 
 Grantees under
the Plan will be such full or part-time officers and other employees, directors, Consultants and key persons of the Company and any Subsidiary who are selected from time to time by the Committee in its sole discretion; provided,
however, that Awards shall be granted only to those individuals described in Rule 701(c) of the Securities Act. 
 SECTION 5. STOCK OPTIONS

 Upon the grant of a Stock Option, the Company and the grantee shall enter into an Award Agreement. The terms and conditions of each such
Award Agreement shall be determined by the Committee, and such terms and conditions may differ among individual Awards and grantees. 

Stock Options granted under the Plan may be either Incentive Stock Options or Non-Qualified Stock Options. Incentive Stock Options may be
granted only to employees of the Company or any Subsidiary that is a “subsidiary corporation” within the meaning of Section 424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be
deemed a Non-Qualified Stock Option. 
 (a) Terms of Stock Options. The Committee in its discretion may grant Stock Options to those
individuals who meet the eligibility requirements of Section 4. Stock Options shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the
Committee shall deem desirable. 
 (i) Exercise Price. The exercise price per share for the Shares covered by a Stock Option shall be
determined by the Committee at the time of grant but shall not be less than 100 percent of the Fair Market Value on the Grant Date. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the exercise price per share for the
Shares covered by such Incentive Stock Option shall not be less than 110 percent of the Fair Market Value on the Grant Date. 

  
 8 

 (ii) Option Term. The term of each Stock Option shall be fixed by the Committee, but no
Stock Option shall be exercisable more than ten years from the Grant Date. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the Grant Date. 

(iii) Exercisability; Rights of a Stockholder. Stock Options shall become exercisable and/or vested at such time or times, whether or
not in installments, as shall be determined by the Committee at or after the Grant Date. The Award Agreement may permit a grantee to exercise all or a portion of a Stock Option immediately at grant; provided that the Shares issued upon such exercise
shall be subject to restrictions and a vesting schedule identical to the vesting schedule of the related Stock Option, such Shares shall be deemed to be Restricted Stock for purposes of the Plan, and the optionee may be required to enter into an
additional or new Award Agreement as a condition to exercise of such Stock Option. An optionee shall have the rights of a stockholder only as to Shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. An optionee
shall not be deemed to have acquired any Shares unless and until a Stock Option shall have been exercised pursuant to the terms of the Award Agreement and this Plan and the optionee’s name has been entered on the books of the Company as a
stockholder. 
 (iv) Method of Exercise. Stock Options may be exercised by an optionee in whole or in part, by the optionee giving
written or electronic notice of exercise to the Company, specifying the number of Shares to be purchased. Payment of the purchase price may be made by one or more of the following methods (or any combination thereof) to the extent provided in the
Award Agreement: 
 (A) In cash, by certified or bank check, by wire transfer of immediately available funds, or other
instrument acceptable to the Committee; 
 (B) If permitted by the Committee, by the optionee delivering to the Company a
promissory note, if the Board has expressly authorized the loan of funds to the optionee for the purpose of enabling or assisting the optionee to effect the exercise of his or her Stock Option; provided, that at least so much of the exercise
price as represents the par value of the Stock shall be paid in cash if required by state law; 
 (C) If permitted by the
Committee and the Initial Public Offering has occurred (or the Stock otherwise becomes publicly-traded), through the delivery (or attestation to the ownership) of Shares that have been purchased by the optionee on the open market or that are
beneficially owned by the optionee and are not then subject to restrictions under any Company plan. To the extent required to avoid variable accounting treatment under ASC 718 or other applicable accounting rules, such surrendered Shares if
originally purchased from the Company shall have been owned by the optionee for at least six months. Such surrendered Shares shall be valued at Fair Market Value on the exercise date; 

  
 9 

 (D) If permitted by the Committee and the Initial Public Offering has occurred
(or the Stock otherwise becomes publicly-traded), by the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and
acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of
indemnity and other agreements as the Committee shall prescribe as a condition of such payment procedure; or 
 (E) If
permitted by the Committee, and only with respect to Stock Options that are not Incentive Stock Options, by a “net exercise” arrangement pursuant to which the Company will reduce the number of Shares issuable upon exercise by the largest
whole number of Shares with a Fair Market Value that does not exceed the aggregate exercise price. 
 Payment instruments will be received
subject to collection. No certificates for Shares so purchased will be issued to the optionee or, with respect to uncertificated Stock, no transfer to the optionee on the records of the Company will take place, until the Company has completed all
steps it has deemed necessary to satisfy legal requirements relating to the issuance and sale of the Shares, which steps may include, without limitation, (i) receipt of a representation from the optionee at the time of exercise of the Option
that the optionee is purchasing the Shares for the optionee’s own account and not with a view to any sale or distribution of the Shares or other representations relating to compliance with applicable law governing the issuance of securities,
(ii) the legending of the certificate (or notation on any book entry) representing the Shares to evidence the foregoing restrictions, and (iii) obtaining from optionee payment or provision for all withholding taxes due as a result of the
exercise of the Option. The delivery of certificates representing the shares of Stock (or the transfer to the optionee on the records of the Company with respect to uncertificated Stock) to be purchased pursuant to the exercise of a Stock Option
will be contingent upon (A) receipt from the optionee (or a purchaser acting in his or her stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such Shares and the fulfillment of any other
requirements contained in the Award Agreement or applicable provisions of laws and (B) if required by the Company, the optionee shall have entered into any stockholders agreements or other agreements with the Company and/or certain other of the
Company’s stockholders relating to the Stock. In the event an optionee chooses to pay the purchase price by previously-owned Shares through the attestation method, the number of Shares transferred to the optionee upon the exercise of the Stock
Option shall be net of the number of Shares attested to. 
 (b) Annual Limit on Incentive Stock Options. To the extent required for
“incentive stock option” treatment under Section 422 of the Code, the aggregate Fair Market Value (determined as of the Grant Date) of the Shares with respect to which Incentive Stock Options granted under the Plan and any other plan
of the Company or its parent and any Subsidiary that become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000 or such other limit as may be in effect from time to time under Section 422 of the
Code. To the extent that any Stock Option exceeds this limit, it shall constitute a Non-Qualified Stock Option. 

  
 10 

 (c) Termination. Any portion of a Stock Option that is not vested and exercisable on the
date of termination of an optionee’s Service Relationship shall immediately expire and be null and void. Once any portion of the Stock Option becomes vested and exercisable, the optionee’s right to exercise such portion of the Stock Option
(or the optionee’s representatives and legatees as applicable) in the event of a termination of the optionee’s Service Relationship shall continue until the earliest of: (i) the date which is: (A) 12 months following the date on
which the optionee’s Service Relationship terminates due to death or Disability (or such longer period of time as determined by the Committee and set forth in the applicable Award Agreement), or (B) three months following the date on which
the optionee’s Service Relationship terminates if the termination is due to any reason other than death or Disability (or such longer period of time as determined by the Committee and set forth in the applicable Award Agreement), or
(ii) the Expiration Date set forth in the Award Agreement; provided that notwithstanding the foregoing, an Award Agreement may provide that if the optionee’s Service Relationship is terminated for Cause, the Stock Option shall
terminate immediately and be null and void upon the date of the optionee’s termination and shall not thereafter be exercisable. 
 SECTION 6.
RESTRICTED STOCK AWARDS 
 (a) Nature of Restricted Stock Awards. The Committee may, in its sole discretion, grant (or sell at
par value or such other purchase price determined by the Committee) to an eligible individual under Section 4 hereof a Restricted Stock Award under the Plan. The Committee shall determine the restrictions and conditions applicable to each
Restricted Stock Award at the time of grant. Conditions may be based on continuing employment (or other Service Relationship), achievement of pre-established performance goals and objectives and/or such other criteria as the Committee may determine.
Upon the grant of a Restricted Stock Award, the Company and the grantee shall enter into an Award Agreement. The terms and conditions of each such Award Agreement shall be determined by the Committee, and such terms and conditions may differ among
individual Awards and grantees. 
 (b) Rights as a Stockholder. Upon the grant of the Restricted Stock Award and payment of any
applicable purchase price, a grantee of Restricted Stock shall be considered the record owner of and shall be entitled to vote the Restricted Stock if, and to the extent, such Shares are entitled to voting rights, subject to such conditions
contained in the Award Agreement. The grantee shall be entitled to receive all dividends and any other distributions declared on the Shares; provided, however, that the Company is under no duty to declare any such dividends or to make
any such distribution. Unless the Committee shall otherwise determine, certificates evidencing the Restricted Stock shall remain in the possession of the Company until such Restricted Stock is vested as provided in subsection (d) below of this
Section, and the grantee shall be required, as a condition of the grant, to deliver to the Company a stock power endorsed in blank and such other instruments of transfer as the Committee may prescribe. 

(c) Restrictions. Restricted Stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as
specifically provided herein or in the Award Agreement. Except as may otherwise be provided by the Committee either in the Award Agreement or, subject to Section 12 below, in writing after the Award Agreement is issued, if a grantee’s
Service Relationship with the Company and any Subsidiary terminates, the Company or its assigns shall have the right, as may be specified in the relevant instrument, to repurchase some or all of the Shares subject to the Award at such purchase price
as is set forth in the Award Agreement. 

  
 11 

 (d) Vesting of Restricted Stock. The Committee at the time of grant shall specify in the
Award Agreement the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the substantial risk of forfeiture imposed shall lapse and the Restricted
Stock shall become vested, subject to such further rights of the Company or its assigns as may be specified in the Award Agreement. 
 SECTION 7.
UNRESTRICTED STOCK AWARDS 
 The Committee may, in its sole discretion, grant (or sell at par value or such other purchase price
determined by the Committee) to an eligible person under Section 4 hereof an Unrestricted Stock Award under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash
compensation due to such grantee. 
 SECTION 8. RESTRICTED STOCK UNITS  

(a) Nature of Restricted Stock Units. The Committee may, in its sole discretion, grant to an eligible person under Section 4 hereof
Restricted Stock Units under the Plan. The Committee shall determine the restrictions and conditions applicable to each Restricted Stock Unit at the time of grant. Vesting conditions may be based on continuing employment (or other Service
Relationship), achievement of pre-established performance goals and objectives and/or other such criteria as the Committee may determine. Upon the grant of Restricted Stock Units, the grantee and the Company shall enter into an Award Agreement. The
terms and conditions of each such Award Agreement shall be determined by the Committee and may differ among individual Awards and grantees. On or promptly following the vesting date or dates applicable to any Restricted Stock Unit, but in no event
later than March 15 of the year following the year in which such vesting occurs, such Restricted Stock Unit(s) shall be settled in the form of cash or shares of Stock, as specified in the Award Agreement. Restricted Stock Units may not be sold,
assigned, transferred, pledged, or otherwise encumbered or disposed of. 
 (b) Rights as a Stockholder. A grantee shall have the
rights of a stockholder only as to Shares, if any, acquired upon settlement of Restricted Stock Units. A grantee shall not be deemed to have acquired any such Shares unless and until the Restricted Stock Units shall have been settled in Shares
pursuant to the terms of the Plan and the Award Agreement, the Company shall have issued and delivered a certificate representing the Shares to the grantee (or transferred on the records of the Company with respect to uncertificated stock), and the
grantee’s name has been entered in the books of the Company as a stockholder. 
 (c) Termination. Except as may otherwise be
provided by the Committee either in the Award Agreement or in writing after the Award Agreement is issued, a grantee’s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee’s cessation of
Service Relationship with the Company and any Subsidiary for any reason. 

  
 12 

 SECTION 9. TRANSFER RESTRICTIONS; COMPANY RIGHT OF FIRST REFUSAL; COMPANY REPURCHASE RIGHTS 

(a) Restrictions on Transfer. 

(i) Non-Transferability of Stock Options. Stock Options and, prior to exercise, the Shares issuable upon exercise of such Stock Option,
shall not be transferable by the optionee otherwise than by will, or by the laws of descent and distribution, and all Stock Options shall be exercisable, during the optionee’s lifetime, only by the optionee, or by the optionee’s legal
representative or guardian in the event of the optionee’s incapacity. Notwithstanding the foregoing, the Committee, in its sole discretion, may provide in the Award Agreement regarding a given Stock Option that the optionee may transfer by
gift, without consideration for the transfer, his or her Non-Qualified Stock Options to his or her family members (as defined in Rule 701 of the Securities Act), to trusts for the benefit of such family
members, or to partnerships in which such family members are the only partners (to the extent such trusts or partnerships are considered “family members” for purposes of Rule 701 of the Securities Act), provided that the transferee agrees
in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award Agreement, including the execution of a stock power upon the issuance of Shares. Stock Options, and the Shares issuable upon exercise of
such Stock Options, shall be restricted as to any pledge, hypothecation, or other transfer, including any short position, any “put equivalent position” (as defined in the Exchange Act) or any “call equivalent position” (as
defined in the Exchange Act) prior to exercise. 
 (ii) Shares. No Shares shall be sold, assigned, transferred, pledged, hypothecated,
given away or in any other manner disposed of or encumbered, whether voluntarily or by operation of law, unless (i) the transfer is in compliance with the terms of the applicable Award Agreement, all applicable securities laws (including,
without limitation, the Securities Act), and with the terms and conditions of this Section 9, (ii) the transfer does not cause the Company to become subject to the reporting requirements of the Exchange Act, and (iii) the transferee
consents in writing to be bound by the provisions of the Plan and the Award Agreement, including this Section 9. In connection with any proposed transfer, the Committee may require the transferor to provide at the transferor’s own expense
an opinion of counsel to the transferor, satisfactory to the Committee, that such transfer is in compliance with all foreign, federal and state securities laws (including, without limitation, the Securities Act). Any attempted transfer of Shares not
in accordance with the terms and conditions of this Section 9 shall be null and void, and the Company shall not reflect on its records any change in record ownership of any Shares as a result of any such transfer, shall otherwise refuse to
recognize any such transfer and shall not in any way give effect to any such transfer of Shares. The Company shall be entitled to seek protective orders, injunctive relief and other remedies available at law or in equity including, without
limitation, seeking specific performance or the rescission of any transfer not made in strict compliance with the provisions of this Section 9. Subject to the foregoing general provisions, and unless otherwise provided in the applicable Award
Agreement, Shares may be transferred pursuant to the following specific terms and conditions (provided that with respect to any transfer of Restricted Stock, all vesting and forfeiture provisions shall continue to apply with respect to the original
recipient): 

  
 13 

 (A) Transfers to Permitted Transferees. The Holder may transfer any or all
of the Shares to one or more Permitted Transferees; provided, however, that following such transfer, such Shares shall continue to be subject to the terms of this Plan (including this Section 9) and such Permitted Transferee(s) shall, as
a condition to any such transfer, deliver a written acknowledgment to that effect to the Company and shall deliver a stock power to the Company with respect to the Shares. Notwithstanding the foregoing, the Holder may not transfer any of the Shares
to a Person whom the Company reasonably determines is a direct competitor or a potential competitor of the Company or any of its Subsidiaries. 

(B) Transfers Upon Death. Upon the death of the Holder, any Shares then held by the Holder at the time of such death and
any Shares acquired after the Holder’s death by the Holder’s legal representative shall be subject to the provisions of this Plan, and the Holder’s estate, executors, administrators, personal representatives, heirs, legatees and
distributees shall be obligated to convey such Shares to the Company or its assigns under the terms contemplated by the Plan and the Award Agreement. 

(b) Right of First Refusal. In the event that a Holder desires at any time to sell or otherwise transfer all or any part of his or her
Shares (other than shares of Restricted Stock which by their terms are not transferrable), the Holder first shall give written notice to the Company of the Holder’s intention to make such transfer. Such notice shall state the number of Shares
that the Holder proposes to sell (the “Offered Shares”), the price and the terms at which the proposed sale is to be made and the name and address of the proposed transferee. At any time within 30 days after the receipt of such notice by
the Company, the Company or its assigns may elect to purchase all or any portion of the Offered Shares at the price and on the terms offered by the proposed transferee and specified in the notice. The Company or its assigns shall exercise this right
by mailing or delivering written notice to the Holder within the foregoing 30-day period. If the Company or its assigns elect to exercise its purchase rights under this Section 9(b), the closing for such purchase shall, in any event, take place
within 45 days after the receipt by the Company of the initial notice from the Holder. In the event that the Company or its assigns do not elect to exercise such purchase right, or in the event that the Company or its assigns do not pay the full
purchase price within such 45-day period, the Holder shall be required to pay a transaction processing fee of $10,000 to the Company (unless waived by the Committee) and then may, within 60 days thereafter, sell the Offered Shares to the proposed
transferee and at the same price and on the same terms as specified in the Holder’s notice. Any Shares not sold to the proposed transferee shall remain subject to the Plan. If the Holder is a party to any stockholders agreements or other
agreements with the Company and/or certain other of the Company’s stockholders relating to the Shares, (i) the transferring Holder shall comply with the requirements of such stockholders agreements or other agreements relating to any
proposed transfer of the Offered Shares, and (ii) any proposed transferee that purchases Offered Shares shall enter into such stockholders agreements or other agreements with the Company and/or certain of the Company’s stockholders
relating to the Offered Shares on the same terms and in the same capacity as the transferring Holder. 

  
 14 

 (c) Company’s Right of Repurchase. 

(i) Right of Repurchase for Unvested Shares Issued Upon the Exercise of an Option. Upon a Termination Event, the Company or its assigns
shall have the right and option to repurchase from a Holder of Shares acquired upon exercise of a Stock Option which are still subject to a risk of forfeiture as of the Termination Event. Such repurchase rights may be exercised by the Company within
the later of (A) six months following the date of such Termination Event or (B) seven months after the acquisition of Shares upon exercise of a Stock Option. The repurchase price shall be equal to the lower of the original per share price
paid by the Holder, subject to adjustment as provided in Section 3(b) of the Plan, or the current Fair Market Value of such Shares as of the date the Company elects to exercise its repurchase rights. 

(ii) Right of Repurchase With Respect to Restricted Stock. Upon a Termination Event, the Company or its assigns shall have the right and
option to repurchase from a Holder of Shares received pursuant to a Restricted Stock Award any Shares that are still subject to a risk of forfeiture as of the Termination Event. Such repurchase right may be exercised by the Company within six months
following the date of such Termination Event. The repurchase price shall be the lower of the original per share purchase price paid by the Holder, subject to adjustment as provided in Section 3(b) of the Plan, or the current Fair Market Value
of such Shares as of the date the Company elects to exercise its repurchase rights. 
 (iii) Procedure. Any repurchase right of the
Company shall be exercised by the Company or its assigns by giving the Holder written notice on or before the last day of the repurchase period of its intention to exercise such repurchase right. Upon such notification, the Holder shall promptly
surrender to the Company, free and clear of any liens or encumbrances, any certificates representing the Shares being purchased, together with a duly executed stock power for the transfer of such Shares to the Company or the Company’s assignee
or assignees. Upon the Company’s or its assignee’s receipt of the certificates from the Holder, the Company or its assignee or assignees shall deliver to him, her or them a check for the applicable repurchase price; provided,
however, that the Company may pay the repurchase price by offsetting and canceling any indebtedness then owed by the Holder to the Company. 

(d) Reserved. 
 (e)
Escrow Arrangement. 
 (i) Escrow. In order to carry out the provisions of this Section 9 of this Plan more effectively,
the Company shall hold any Shares issued pursuant to Awards granted under the Plan in escrow together with separate stock powers executed by the Holder in blank for transfer. The Company shall not dispose of the Shares except as otherwise provided
in this Plan. In the event of any repurchase by the Company (or any of its assigns), the Company is hereby authorized by the Holder, as the Holder’s attorney-in-fact, to date and complete the stock powers necessary for the transfer of the
Shares being purchased and to transfer such Shares in accordance with the terms hereof. At such time as any Shares are no longer subject to the Company’s repurchase and first refusal rights, the Company shall, at the written request of the
Holder, deliver to the Holder a certificate representing such Shares with the balance of the Shares to be held in escrow pursuant to this Section. 

  
 15 

 (ii) Remedy. Without limitation of any other provision of this Plan or other rights, in
the event that a Holder or any other Person is required to sell a Holder’s Shares pursuant to the provisions of Sections 9(b) or (c) hereof and in the further event that he or she refuses or for any reason fails to deliver to the Company
or its designated purchaser of such Shares the certificate or certificates evidencing such Shares together with a related stock power, the Company or such designated purchaser may deposit the applicable purchase price for such Shares with a bank
designated by the Company, or with the Company’s independent public accounting firm, as agent or trustee, or in escrow, for such Holder or other Person, to be held by such bank or accounting firm for the benefit of and for delivery to him, her,
them or it, and/or, in its discretion, pay such purchase price by offsetting any indebtedness then owed by such Holder as provided above. Upon any such deposit and/or offset by the Company or its designated purchaser of such amount and upon notice
to the Person who was required to sell the Shares to be sold pursuant to the provisions of Sections 9(b) or (c), such Shares shall at such time be deemed to have been sold, assigned, transferred and conveyed to such purchaser, such Holder shall have
no further rights thereto (other than the right to withdraw the payment thereof held in escrow, if applicable), and the Company shall record such transfer in its stock transfer book or in any appropriate manner. 

(f) Lockup Provision. If requested by the Company, a Holder shall not sell or otherwise transfer or dispose of any Shares (including,
without limitation, pursuant to Rule 144 under the Securities Act) held by him or her for such period following the effective date of a public offering by the Company of Shares as the Company shall specify reasonably and in good faith. If requested
by the underwriter engaged by the Company, each Holder shall execute a separate letter confirming his or her agreement to comply with this Section. 

(g) Adjustments for Changes in Capital Structure. If, as a result of any reorganization, recapitalization, reclassification, stock
dividend, stock split, reverse stock split or other similar change in the Common Stock, the outstanding Shares are increased or decreased or are exchanged for a different number or kind of securities of the Company, the restrictions contained in
this Section 9 shall apply with equal force to additional and/or substitute securities, if any, received by Holder in exchange for, or by virtue of his or her ownership of, Shares. 

(h) Termination. The terms and provisions of Section 9(b) and Section 9(c) (except for the Company’s right to repurchase
Shares still subject to a risk of forfeiture upon a Termination Event) shall terminate upon the closing of the Company’s Initial Public Offering or upon consummation of any Sale Event, in either case as a result of which Shares are registered
under Section 12 of the Exchange Act and publicly-traded on any national security exchange. 
 SECTION 10. TAX WITHHOLDING 

(a) Payment by Grantee. Each grantee shall, no later than the date as of which the value of an Award or of any Shares or other amounts
received thereunder first becomes includable in the gross income of the grantee for income tax purposes, pay to the Company, or make arrangements satisfactory to the Committee regarding payment of, any Federal, state, or local taxes of any kind
required by law to be withheld by the Company with respect to such income. The Company and any Subsidiary shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The
Company’s obligation to deliver stock certificates (or evidence of book entry) to any grantee is subject to and conditioned on any such tax withholding obligations being satisfied by the grantee. 

  
 16 

 (b) Payment in Stock. The Company’s minimum required tax withholding obligation may
be satisfied, in whole or in part, by the Company withholding from Shares to be issued pursuant to an Award a number of Shares having an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the minimum
withholding amount due. 
 SECTION 11. SECTION 409A AWARDS. 

To the extent that any Award is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A
(a “409A Award”), the Award shall be subject to such additional rules and requirements as may be specified by the Committee from time to time. In this regard, if any amount under a 409A Award is payable upon a “separation from
service” (within the meaning of Section 409A) to a grantee who is considered a “specified employee” (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of
(i) six months and one day after the grantee’s separation from service, or (ii) the grantee’s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or
additional tax imposed pursuant to Section 409A. The Company makes no representation or warranty and shall have no liability to any grantee under the Plan or any other Person with respect to any penalties or taxes under Section 409A that
are, or may be, imposed with respect to any Award. 
 SECTION 12. AMENDMENTS AND TERMINATION 

The Board may, at any time, amend or discontinue the Plan and the Committee may, at any time, amend or cancel any outstanding Award for the
purpose of satisfying changes in law or for any other lawful purpose, but no such action shall adversely affect rights under any outstanding Award without the consent of the holder of the Award. The Committee may exercise its discretion to reduce
the exercise price of outstanding Stock Options or effect repricing through cancellation of outstanding Stock Options and by granting such holders new Awards in replacement of the cancelled Stock Options. To the extent determined by the Committee to
be required either by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section 422 of the Code or otherwise, Plan amendments shall be subject to approval by the Company stockholders entitled to vote at
a meeting of stockholders. Nothing in this Section 12 shall limit the Board’s or Committee’s authority to take any action permitted pursuant to Section 3(c). The Board reserves the right to amend the Plan and/or the terms of any
outstanding Stock Options to the extent reasonably necessary to comply with the requirements of the exemption pursuant to paragraph (f)(4) of Rule 12h-1 of the Exchange Act. 

SECTION 13. STATUS OF PLAN 
 With respect
to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Committee
shall otherwise expressly so determine in connection with any Award. 

  
 17 

 SECTION 14. GENERAL PROVISIONS 

(a) No Distribution; Compliance with Legal Requirements. The Committee may require each person acquiring Shares pursuant to an Award to
represent to and agree with the Company in writing that such person is acquiring the Shares without a view to distribution thereof. No Shares shall be issued pursuant to an Award until all applicable securities law and other legal and stock exchange
or similar requirements have been satisfied. The Committee may require the placing of such stop-orders and restrictive legends on certificates for Stock and Awards as it deems appropriate. 

(b) Delivery of Stock Certificates. Stock certificates to grantees under the Plan shall be deemed delivered for all purposes when the
Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee’s last known address on file with the Company; provided that stock certificates to be held
in escrow pursuant to Section 9 of the Plan shall be deemed delivered when the Company shall have recorded the issuance in its records. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a stock transfer agent
of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee’s last known address on file with the Company, notice of issuance and recorded the
issuance in its records (which may include electronic “book entry” records). 
 (c) No Employment Rights. The
adoption of the Plan and the grant of Awards do not confer upon any Person any right to continued employment or Service Relationship with the Company or any Subsidiary. 

(d) Trading Policy Restrictions. Option exercises and other Awards under the Plan shall be subject to the Company’s insider trading
policy-related restrictions, terms and conditions as may be established by the Committee, or in accordance with policies set by the Committee, from time to time. 

(e) Designation of Beneficiary. Each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries
to exercise any Award on or after the grantee’s death or receive any payment under any Award payable on or after the grantee’s death. Any such designation shall be on a form provided for that purpose by the Committee and shall not be
effective until received by the Committee. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee’s estate. 

(f) Legend. Any certificate(s) representing the Shares shall carry substantially the following legend (and with respect to
uncertificated Stock, the book entries evidencing such shares shall contain the following notation): 
 The transferability of this
certificate and the shares of stock represented hereby are subject to the restrictions, terms and conditions (including repurchase and restrictions against transfers) contained in the Surface Oncology, Inc. 2014 Stock Option and Grant Plan and any
agreements entered into thereunder by and between the company and the holder of this certificate (a copy of which is available at the offices of the company for examination). 

  
 18 

 (g) Information to Holders of Options. In the event the Company is relying on the
exemption from the registration requirements of Section 12(g) of the Exchange Act contained in paragraph (f)(1) of Rule 12h-1 of the Exchange Act, the Company shall provide the information described in Rule 701(e)(3), (4) and (5) of
the Securities Act to all holders of Options in accordance with the requirements thereunder. The foregoing notwithstanding, the Company shall not be required to provide such information unless the optionholder has agreed in writing, on a form
prescribed by the Company, to keep such information confidential. 
 SECTION 15. EFFECTIVE DATE OF PLAN 

The Plan shall become effective upon adoption by the Board and shall be approved by stockholders in accordance with applicable state law and
the Company’s articles of incorporation and bylaws within 12 months thereafter. If the stockholders fail to approve the Plan within 12 months after its adoption by the Board of Directors, then any Awards granted or sold under the Plan shall be
rescinded and no additional grants or sales shall thereafter be made under the Plan. Subject to such approval by stockholders and to the requirement that no Shares may be issued hereunder prior to such approval, Stock Options and other Awards may be
granted hereunder on and after adoption of the Plan by the Board. No grants of Stock Options and other Awards may be made hereunder after the tenth anniversary of the date the Plan is adopted by the Board or the date the Plan is approved by the
Company’s stockholders, whichever is earlier. 
 SECTION 16. GOVERNING LAW 

This Plan, all Awards and any controversy arising out of or relating to this Plan and all Awards shall be governed by and construed in
accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts,
without regard to conflict of law principles that would result in the application of any law other than the law of the Commonwealth of Massachusetts. 

DATE ADOPTED BY THE BOARD OF DIRECTORS: November 5, 2014 

DATE APPROVED BY THE STOCKHOLDERS: November 5, 2014 

  
 19 

 SURFACE ONCOLOGY, INC. 

AMENDMENT NO. 1 TO 
 2014
STOCK OPTION AND GRANT PLAN 
 WHEREAS, the Board of Directors of Surface Oncology, Inc. (the “Company”) approved and
adopted the 2014 Stock Option and Grant Plan (the “Plan”) of the Company on November 5, 2014, and the stockholders of the Company approved and adopted the Plan on November 5, 2014; and 

WHEREAS, the Board of Directors and the stockholders of the Company have determined that it is in the best interest of the Company to amend
the Plan as set forth in this Amendment. 
 NOW, THEREFORE, the Plan is amended as follows: 

 

	1.	Amendment of the Plan 

 1.01.    Section 3(a) of the
Plan is hereby amended and restated in its entirety to read as follows: 
 “Stock Issuable. The maximum number of Shares
reserved and available for issuance under the Plan shall be 3,742,353 Shares, subject to adjustment as provided in Section 3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired
by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax
withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award, and no more than 37,423,530 Shares may
be issued pursuant to Incentive Stock Options. The Shares available for issuance under the Plan may be authorized but unissued Shares or Shares reacquired by the Company. Beginning on the date that the Company becomes subject to Section 162(m)
of the Code, Options with respect to no more than 3,742,353 Shares shall be granted to any one individual in any calendar year period.” 
  

	2.	Miscellaneous. 

 2.01.    Effect. Except as
amended hereby, the Plan shall remain in full force and effect. 
 2.02.    Defined Terms. All capitalized
terms used but not specifically defined herein shall have the same meanings given such terms in the Plan unless the context clearly indicates or dictates a contrary meaning. 

2.03.    Governing Law. This Amendment shall be governed by and construed in accordance with the General
Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of
law principles that would result in the application of any law other than the law of the Commonwealth of Massachusetts. 
 ADOPTED BY BOARD OF
DIRECTORS:    November 21, 2014 
 APPROVED BY STOCKHOLDERS:     November 21, 2014 

 SURFACE ONCOLOGY, INC. 

AMENDMENT NO. 2 TO 
 2014
STOCK OPTION AND GRANT PLAN 
 WHEREAS, the Board of Directors of Surface Oncology, Inc. (the “Company”) approved and
adopted the 2014 Stock Option and Grant Plan (the “Plan”) of the Company on November 5, 2014, and the stockholders of the Company approved and adopted the Plan on November 5, 2014; and 

WHEREAS, the Board of Directors approved and adopted Amendment No. 1 to the Plan (“Amendment 1”) on November 21,
2014, and the stockholders of the Company approved and adopted Amendment 1 on November 21, 2014; and 
 WHEREAS, the Board of Directors
and the stockholders of the Company have determined that it is in the best interest of the Company to further amend the Plan as set forth in this Amendment. 

NOW, THEREFORE, the Plan is amended as follows: 
  

	1.	Amendment of the Plan 

 1.01.    Section 3(a) of the
Plan is hereby amended and restated in its entirety to read as follows: 
 “Stock Issuable. The maximum number of Shares
reserved and available for issuance under the Plan shall be 5,771,764 Shares, subject to adjustment as provided in Section 3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired
by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax
withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award, and no more than 57,717,640 Shares may
be issued pursuant to Incentive Stock Options. The Shares available for issuance under the Plan may be authorized but unissued Shares or Shares reacquired by the Company. Beginning on the date that the Company becomes subject to Section 162(m)
of the Code, Options with respect to no more than 5,771,764 Shares shall be granted to any one individual in any calendar year period.” 
  

	2.	Miscellaneous. 

 2.01.    Effect. Except as
amended hereby, the Plan shall remain in full force and effect. 
 2.02.    Defined Terms. All capitalized
terms used but not specifically defined herein shall have the same meanings given such terms in the Plan unless the context clearly indicates or dictates a contrary meaning. 

2.03.    Governing Law. This Amendment shall be governed by and construed in accordance with the General
Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of
law principles that would result in the application of any law other than the law of the Commonwealth of Massachusetts. 
 ADOPTED BY BOARD OF
DIRECTORS:    December 4, 2015 
 APPROVED BY STOCKHOLDERS:     December 22, 2015 

 SURFACE ONCOLOGY, INC. 

AMENDMENT NO. 3 TO 
 2014
STOCK OPTION AND GRANT PLAN 
 WHEREAS, the Board of Directors of Surface Oncology, Inc. (the “Company”) approved and
adopted the 2014 Stock Option and Grant Plan (the “Plan”) of the Company on November 5, 2014, and the stockholders of the Company approved and adopted the Plan on November 5, 2014; and 

WHEREAS, the Board of Directors approved and adopted Amendment No. 1 to the Plan (“Amendment 1”) on November 21,
2014, and the stockholders of the Company approved and adopted Amendment 1 on November 21, 2014; and 
 WHEREAS, the Board of Directors
approved and adopted Amendment No. 2 to the Plan (“Amendment 2”) on December 4, 2015, and the stockholders of the Company approved and adopted Amendment 2 on December 22, 2015; and 

WHEREAS, the Board of Directors and the stockholders of the Company have determined that it is in the best interest of the Company to further
amend the Plan as set forth in this Amendment. 
 NOW, THEREFORE, the Plan is amended as follows: 

 

	1.	Amendment of the Plan 

 1.01.    Section 3(a) of the
Plan is hereby amended and restated in its entirety to read as follows: 
 “Stock Issuable. The maximum number of Shares
reserved and available for issuance under the Plan shall be 7,977,646 Shares, subject to adjustment as provided in Section 3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired
by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax
withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award, and no more than 79,776,460 Shares may
be issued pursuant to Incentive Stock Options. The Shares available for issuance under the Plan may be authorized but unissued Shares or Shares reacquired by the Company. Beginning on the date that the Company becomes subject to Section 162(m)
of the Code, Options with respect to no more than 7,977,646 Shares shall be granted to any one individual in any calendar year period.” 
  

	2.	Miscellaneous. 

 2.01.    Effect. Except as
amended hereby, the Plan shall remain in full force and effect. 
 2.02.    Defined Terms. All capitalized
terms used but not specifically defined herein shall have the same meanings given such terms in the Plan unless the context clearly indicates or dictates a contrary meaning. 

2.03.    Governing Law. This Amendment shall be governed by and construed in accordance with the General
Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of
law principles that would result in the application of any law other than the law of the Commonwealth of Massachusetts. 
 ADOPTED BY BOARD OF DIRECTORS:
January 27, 2016     
 APPROVED BY STOCKHOLDERS:    January 28, 2016 

 SURFACE ONCOLOGY, INC. 

AMENDMENT NO. 4 TO 
 2014
STOCK OPTION AND GRANT PLAN 
 WHEREAS, the Board of Directors of Surface Oncology, Inc. (the “Company”) approved and
adopted the 2014 Stock Option and Grant Plan (the “Plan”) of the Company on November 5, 2014, and the stockholders of the Company approved and adopted the Plan on November 5, 2014; and 

WHEREAS, the Board of Directors approved and adopted Amendment No. 1 to the Plan (“Amendment 1”) on November 21,
2014, and the stockholders of the Company approved and adopted Amendment 1 on November 21, 2014; 
 WHEREAS, the Board of Directors
approved and adopted Amendment No. 2 to the Plan (“Amendment 2”) on December 4, 2015, and the stockholders of the Company approved and adopted Amendment 2 on December 22, 2015; 

WHEREAS, the Board of Directors approved and adopted Amendment No. 3 to the Plan (“Amendment 3”) on January 27,
2016, and the stockholders of the Company approved and adopted Amendment 3 on January 28, 2016; and 
 WHEREAS, the Board of Directors
and the stockholders of the Company have determined that it is in the best interest of the Company to further amend the Plan as set forth in this Amendment. 

NOW, THEREFORE, the Plan is amended as follows: 
  

	1.	Amendment of the Plan 

 1.01.    Section 3(a) of the
Plan is hereby amended and restated in its entirety to read as follows: 
 “Stock Issuable. The maximum number of Shares
reserved and available for issuance under the Plan shall be 9,877,646 Shares, subject to adjustment as provided in Section 3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired
by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax
withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award, and no more than 98,776,460 Shares may
be issued pursuant to Incentive Stock Options. The Shares available for issuance under the Plan may be authorized but unissued Shares or Shares reacquired by the Company. Beginning on the date that the Company becomes subject to Section 162(m)
of the Code, Options with respect to no more than 9,877,646 Shares shall be granted to any one individual in any calendar year period.” 
  

	2.	Miscellaneous. 

 2.01.    Effect. Except as
amended hereby, the Plan shall remain in full force and effect. 
 2.02.    Defined Terms. All capitalized
terms used but not specifically defined herein shall have the same meanings given such terms in the Plan unless the context clearly indicates or dictates a contrary meaning. 

 2.03.    Governing Law. This Amendment shall be governed by and
construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of
Massachusetts, without regard to conflict of law principles that would result in the application of any law other than the law of the Commonwealth of Massachusetts. 

ADOPTED BY BOARD OF DIRECTORS: March 30, 2017     

APPROVED BY STOCKHOLDERS:    April 19, 2017 

 SURFACE ONCOLOGY, INC. 

AMENDMENT NO. 5 TO 
 2014
STOCK OPTION AND GRANT PLAN 
 WHEREAS, the Board of Directors of Surface Oncology, Inc. (the “Company”) approved and
adopted the 2014 Stock Option and Grant Plan (the “Plan”) of the Company on November 5, 2014, and the stockholders of the Company approved and adopted the Plan on November 5, 2014; and 

WHEREAS, the Board of Directors approved and adopted Amendment No. 1 to the Plan (“Amendment 1”) on November 21,
2014, and the stockholders of the Company approved and adopted Amendment 1 on November 21, 2014; 
 WHEREAS, the Board of Directors
approved and adopted Amendment No. 2 to the Plan (“Amendment 2”) on December 4, 2015, and the stockholders of the Company approved and adopted Amendment 2 on December 22, 2015; 

WHEREAS, the Board of Directors approved and adopted Amendment No. 3 to the Plan (“Amendment 3”) on January 27,
2016, and the stockholders of the Company approved and adopted Amendment 3 on January 28, 2016; 
 WHEREAS, the Board of Directors
approved and adopted Amendment No. 4 to the Plan (“Amendment 4”) on March 30, 2017, and the stockholders of the Company approved and adopted Amendment 4 on April 19, 2017; 

WHEREAS, the Board of Directors and the stockholders of the Company have determined that it is in the best interest of the Company to further
amend the Plan as set forth in this Amendment. 
 NOW, THEREFORE, the Plan is amended as follows: 

 

	1.	Amendment of the Plan 

 1.01. Section 3(a) of the Plan is hereby amended
and restated in its entirety to read as follows: 
 “Stock Issuable. The maximum number of Shares reserved and available for
issuance under the Plan shall be 9,897,646 Shares, subject to adjustment as provided in Section 3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired by the Company prior to
vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall be added back to
the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award, and no more than 98,976,460 Shares may be issued pursuant to Incentive
Stock Options. The Shares available for issuance under the Plan may be authorized but unissued Shares or Shares reacquired by the Company. Beginning on the date that the Company becomes subject to Section 162(m) of the Code, Options with
respect to no more than 9,897,646 Shares shall be granted to any one individual in any calendar year period.” 

	2.	Miscellaneous. 

 2.01. Effect. Except as amended hereby, the Plan
shall remain in full force and effect. 
 2.02. Defined Terms. All capitalized terms used but not specifically defined herein
shall have the same meanings given such terms in the Plan unless the context clearly indicates or dictates a contrary meaning. 

2.03. Governing Law. This Amendment shall be governed by and construed in accordance with the General Corporation Law of the
State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that
would result in the application of any law other than the law of the Commonwealth of Massachusetts. 
 ADOPTED BY BOARD OF DIRECTORS: February 12,
2018 
 APPROVED BY STOCKHOLDERS: February 12, 2018 

  
 2 

 SURFACE ONCOLOGY, INC. 

AMENDMENT NO. 6 TO 
 2014
STOCK OPTION AND GRANT PLAN 
 WHEREAS, the Board of Directors of Surface Oncology, Inc. (the “Company”) approved and
adopted the 2014 Stock Option and Grant Plan (the “Plan”) of the Company on November 5, 2014, and the stockholders of the Company approved and adopted the Plan on November 5, 2014; and 

WHEREAS, the Board of Directors approved and adopted Amendment No. 1 to the Plan (“Amendment 1”) on November 21,
2014, and the stockholders of the Company approved and adopted Amendment 1 on November 21, 2014; 
 WHEREAS, the Board of Directors
approved and adopted Amendment No. 2 to the Plan (“Amendment 2”) on December 4, 2015, and the stockholders of the Company approved and adopted Amendment 2 on December 22, 2015; 

WHEREAS, the Board of Directors approved and adopted Amendment No. 3 to the Plan (“Amendment 3”) on January 27,
2016, and the stockholders of the Company approved and adopted Amendment 3 on January 28, 2016; 
 WHEREAS, the Board of Directors
approved and adopted Amendment No. 4 to the Plan (“Amendment 4”) on March 30, 2017, and the stockholders of the Company approved and adopted Amendment 4 on April 19, 2017; 

WHEREAS, the Board of Directors approved and adopted Amendment No. 5 to the Plan (“Amendment 5”) on February 12,
2018, and the stockholders of the Company approved and adopted Amendment 6 on February 12, 2018; 
 WHEREAS, the Board of Directors and
the stockholders of the Company have determined that it is in the best interest of the Company to further amend the Plan as set forth in this Amendment. 

NOW, THEREFORE, the Plan is amended as follows: 
  

	1.	Amendment of the Plan 

 1.01.    Section 3(a) of the
Plan is hereby amended and restated in its entirety to read as follows: 
 “Stock Issuable. The maximum number of Shares
reserved and available for issuance under the Plan shall be 11,197,646 Shares, subject to adjustment as provided in Section 3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired
by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax
withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award, and no more than 11,197,646 Shares may
be issued pursuant to Incentive Stock Options. The Shares available for issuance under the Plan may be authorized but unissued Shares or Shares reacquired by the Company. Beginning on the date that the Company becomes subject to Section 162(m)
of the Code, Options with respect to no more than 11,197,646 Shares shall be granted to any one individual in any calendar year period.” 

	2.	Miscellaneous. 

 2.01.    Effect. Except as
amended hereby, the Plan shall remain in full force and effect. 
 2.02.    Defined Terms. All capitalized
terms used but not specifically defined herein shall have the same meanings given such terms in the Plan unless the context clearly indicates or dictates a contrary meaning. 

2.03.    Governing Law. This Amendment shall be governed by and construed in accordance with the General
Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of
law principles that would result in the application of any law other than the law of the Commonwealth of Massachusetts. 
 ADOPTED BY BOARD OF DIRECTORS:
March 2, 2018 
 APPROVED BY STOCKHOLDERS: March 2, 2018 

 INCENTIVE STOCK OPTION GRANT NOTICE 

UNDER THE SURFACE ONCOLOGY, INC. 

2014 STOCK OPTION AND GRANT PLAN 

Pursuant to the Surface Oncology, Inc. 2014 Stock Option and Grant Plan (the “Plan”), Surface Oncology, Inc., a Delaware corporation
(together with any successor, the “Company”), has granted to the individual named below, an option (the “Stock Option”) to purchase on or prior to the Expiration Date, or such earlier date as is specified herein, all or any part
of the number of shares of Common Stock, par value $0.0001 per share (“Common Stock”), of the Company indicated below (the “Shares”), at the Option Exercise Price per share, subject to the terms and conditions set forth in this
Incentive Stock Option Grant Notice (the “Grant Notice”), the attached Incentive Stock Option Agreement (the “Agreement”) and the Plan. This Stock Option is intended to qualify as an “incentive stock option” as defined
in Section 422(b) of the Internal Revenue Code of 1986, as amended from time to time (the “Code”). To the extent that any portion of the Stock Option does not so qualify, it shall be deemed a
non-qualified stock option. 
  

			
	Name of Optionee:	  	                                 (the
“Optionee”)
		
	No. of Shares:	  	                     Shares of Common Stock
		
	Grant Date:	  	                                
		
	Vesting Commencement Date:	  	                                 (the “Vesting Commencement
Date”)
		
	Expiration Date:	  	                                 (the “Expiration
Date”)
		
	Option Exercise Price/Share:	  	$                               (the “Option Exercise
Price”)
		
	Vesting Schedule:	  	25 percent of the Shares shall vest and become exercisable on the first anniversary of the Vesting Commencement Date; provided that the Optionee continues to have a Service Relationship with the Company at such time.
Thereafter, the remaining 75 percent of the Shares shall vest and become exercisable in 36 equal monthly installments following the first anniversary of the Vesting Commencement Date, provided the Optionee continues to have a Service
Relationship with the Company on each vesting date. Notwithstanding anything in the Agreement to the contrary, in the case of a Sale Event, this Stock Option and the Shares shall be treated as provided in Section 3(c) of the Plan.

 Attachments: Incentive Stock Option Agreement, 2014 Stock Option and Grant Plan  

 INCENTIVE STOCK OPTION AGREEMENT 

UNDER THE SURFACE ONCOLOGY 

2014 STOCK OPTION AND GRANT PLAN 

All capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Grant Notice and the Plan.

 1. Vesting, Exercisability and Termination. 

(a) No portion of this Stock Option may be exercised until such portion shall have vested and become exercisable. 

(b) Except as set forth below, and subject to the determination of the Committee in its sole discretion to accelerate the vesting schedule
hereunder, this Stock Option shall be vested and exercisable on the respective dates indicated below: 
 (i) This Stock
Option shall initially be unvested and unexercisable. 
 (ii) This Stock Option shall vest and become exercisable in
accordance with the Vesting Schedule set forth in the Grant Notice. 
 (c) Termination. Except as may otherwise be provided by the
Committee, if the Optionee’s Service Relationship is terminated, the period within which to exercise this Stock Option will be subject to earlier termination as set forth below (and if not exercised within such period, shall thereafter
terminate subject, in each case, to Section 3(c) of the Plan): 
 (i) Termination Due to Death or Disability. If
the Optionee’s Service Relationship terminates by reason of such Optionee’s death or Disability, this Stock Option may be exercised, to the extent exercisable on the date of such termination, by the Optionee, the Optionee’s legal
representative or legatee for a period of 12 months from the date of death or Disability or until the Expiration Date, if earlier. 

(ii) Other Termination. If the Optionee’s Service Relationship terminates for any reason other than death or
Disability, and unless otherwise determined by the Committee, this Stock Option may be exercised, to the extent exercisable on the date of termination, for a period of 90 days from the date of termination or until the Expiration Date, if earlier;
provided however, if the Optionee’s Service Relationship is terminated for Cause, this Stock Option shall terminate immediately upon the date of such termination. 

For purposes hereof, the Committee’s determination of the reason for termination of the Optionee’s Service Relationship shall be
conclusive and binding on the Optionee and his or her representatives or legatees. Any portion of this Stock Option that is not vested and exercisable on the date of termination of the Service Relationship shall terminate immediately and be null and
void. 

  
 2 

 (d) It is understood and intended that this Stock Option is intended to qualify as an
“incentive stock option” as defined in Section 422 of the Code to the extent permitted under applicable law. Accordingly, the Optionee understands that in order to obtain the benefits of an incentive stock option under
Section 422 of the Code, no sale or other disposition may be made of Shares for which incentive stock option treatment is desired within the one-year period beginning on the day after the day of the
transfer of such Shares to him or her, nor within the two-year period beginning on the day after Grant Date of this Stock Option and further that this Stock Option must be exercised within three months after
termination of employment as an employee (or 12 months in the case of death or disability) to qualify as an incentive stock option. If the Optionee disposes (whether by sale, gift, transfer or otherwise) of any such Shares within either of these
periods, he or she will notify the Company within 30 days after such disposition. The Optionee also agrees to provide the Company with any information concerning any such dispositions required by the Company for tax purposes. Further, to the extent
this Stock Option and any other incentive stock options of the Optionee having an aggregate Fair Market Value in excess of $100,000 (determined as of the Grant Date) first become exercisable in any year, such options will not qualify as incentive
stock options. 
 2. Exercise of Stock Option. 

(a) The Optionee may exercise this Stock Option only in the following manner: Prior to the Expiration Date, the Optionee may deliver a Stock
Option exercise notice (an “Exercise Notice”) in the form of Appendix A hereto indicating his or her election to purchase some or all of the Shares with respect to which this Stock Option is then exercisable. Such
notice shall specify the number of Shares to be purchased. Payment of the purchase price may be made by one or more of the methods described in Section 5 of the Plan, subject to the limitations contained in such Section of the Plan, including
the requirement that the Committee specifically approve in advance certain payment methods. 
 (b) Notwithstanding any other provision
hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date. 
 3. Incorporation of Plan.
Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan. 

4. Transferability of Stock Option. This Stock Option is personal to the Optionee and is not transferable by the Optionee in any manner
other than by will or by the laws of descent and distribution. The Stock Option may be exercised during the Optionee’s lifetime only by the Optionee (or by the Optionee’s guardian or personal representative in the event of the
Optionee’s incapacity). The Optionee may elect to designate a beneficiary by providing written notice of the name of such beneficiary to the Company, and may revoke or change such designation at any time by filing written notice of revocation
or change with the Company; such beneficiary may exercise the Optionee’s Stock Option in the event of the Optionee’s death to the extent provided herein. If the Optionee does not designate a beneficiary, or if the designated beneficiary
predeceases the Optionee, the legal representative of the Optionee may exercise this Stock Option to the extent provided herein in the event of the Optionee’s death. 

  
 3 

 5. Restrictions on Transfer of Shares. The Shares acquired upon exercise of the Stock
Option shall be subject to certain transfer restrictions and other limitations including, without limitation, the provisions contained in Section 9 of the Plan. 

6. Miscellaneous Provisions. 

(a) Equitable Relief. The parties hereto agree and declare that legal remedies may be inadequate to enforce the provisions of this
Agreement and that equitable relief, including specific performance and injunctive relief, may be used to enforce the provisions of this Agreement. 

(b) Adjustments for Changes in Capital Structure. If, as a result of any reorganization, recapitalization, reincorporation,
reclassification, stock dividend, stock split, reverse stock split or other similar change in the Common Stock, the outstanding shares of Common Stock are increased or decreased or are exchanged for a different number or kind of securities of the
Company, the restrictions contained in this Agreement shall apply with equal force to additional and/or substitute securities, if any, received by the Optionee in exchange for, or by virtue of his or her ownership of, this Stock Option or Shares
acquired pursuant thereto. 
 (c) Change and Modifications. This Agreement may not be orally changed, modified or terminated, nor
shall any oral waiver of any of its terms be effective. This Agreement may be changed, modified or terminated only by an agreement in writing signed by the Company and the Optionee. 

(d) Governing Law. This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of
Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that would result
in the application of any law other than the law of the Commonwealth of Massachusetts. 
 (e) Headings. The headings are intended
only for convenience in finding the subject matter and do not constitute part of the text of this Agreement and shall not be considered in the interpretation of this Agreement. 

(f) Saving Clause. If any provision(s) of this Agreement shall be determined to be illegal or unenforceable, such determination shall
in no manner affect the legality or enforceability of any other provision hereof. 
 (g) Notices. All notices, requests, consents and
other communications shall be in writing and be deemed given when delivered personally, by telex or facsimile transmission or when received if mailed by first class registered or certified mail, postage prepaid. Notices to the Company or the
Optionee shall be addressed as set forth underneath their signatures below, or to such other address or addresses as may have been furnished by such party in writing to the other. 

(h) Benefit and Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, their
respective successors, assigns, and legal representatives. The Company has the right to assign this Agreement, and such assignee shall become entitled to all the rights of the Company hereunder to the extent of such assignment. 

  
 4 

 (i) Counterparts. For the convenience of the parties and to facilitate execution, this
Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same document. 

(j) Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes
all prior agreements and discussions between the parties concerning such subject matter. 
 7. Dispute Resolution. 

(a) Except as provided below, any dispute arising out of or relating to the Plan or this Stock Option, this Agreement, or the breach,
termination or validity of the Plan, this Stock Option or this Agreement, shall be finally settled by binding arbitration conducted expeditiously in accordance with the J.A.M.S./Endispute Comprehensive Arbitration Rules and Procedures (the
“J.A.M.S. Rules”). The arbitration shall be governed by the United States Arbitration Act, 9 U.S.C. Sections 1 16, and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof. The place
of arbitration shall be Boston, Massachusetts. 
 (b) The arbitration shall commence within 60 days of the date on which a written demand
for arbitration is filed by any party hereto. In connection with the arbitration proceeding, the arbitrator shall have the power to order the production of documents by each party and any third-party witnesses. In addition, each party may take up to
three depositions as of right, and the arbitrator may in his or her discretion allow additional depositions upon good cause shown by the moving party. However, the arbitrator shall not have the power to order the answering of interrogatories or the
response to requests for admission. In connection with any arbitration, each party to the arbitration shall provide to the other, no later than seven business days before the date of the arbitration, the identity of all persons that may testify at
the arbitration and a copy of all documents that may be introduced at the arbitration or considered or used by a party’s witness or expert. The arbitrator’s decision and award shall be made and delivered within six months of the selection
of the arbitrator. The arbitrator’s decision shall set forth a reasoned basis for any award of damages or finding of liability. The arbitrator shall not have power to award damages in excess of actual compensatory damages and shall not multiply
actual damages or award punitive damages, and each party hereby irrevocably waives any claim to such damages. 
 (c) The Company, the
Optionee, each party to the Agreement and any other holder of Shares issued pursuant to this Agreement (each, a “Party”) covenants and agrees that such party will participate in the arbitration in good faith. This Section 7 applies
equally to requests for temporary, preliminary or permanent injunctive relief, except that in the case of temporary or preliminary injunctive relief any party may proceed in court without prior arbitration for the limited purpose of avoiding
immediate and irreparable harm. 

  
 5 

 (d) Each Party (i) hereby irrevocably submits to the jurisdiction of any United States
District Court of competent jurisdiction for the purpose of enforcing the award or decision in any such proceeding, (ii) hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or
proceeding, any claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution (except as protected by applicable law), that the suit, action or proceeding is
brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (iii) hereby waives and agrees not to seek any
review by any court of any other jurisdiction which may be called upon to grant an enforcement of the judgment of any such court. Each Party hereby consents to service of process by registered mail at the address to which notices are to be given.
Each Party agrees that its, his or her submission to jurisdiction and its, his or her consent to service of process by mail is made for the express benefit of each other Party. Final judgment against any Party in any such action, suit or proceeding
may be enforced in other jurisdictions by suit, action or proceeding on the judgment, or in any other manner provided by or pursuant to the laws of such other jurisdiction. 

[SIGNATURE PAGE FOLLOWS] 

  
 6 

 The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to
by the undersigned as of the date first above written. 
  

			
	SURFACE ONCOLOGY, INC.
		
	By:	 	 
		 	 Name:
 Title:

	
	 Address:

	 	 	 
		
	 	 	 
		
	 	 	 

 The undersigned hereby acknowledges receiving and reviewing a copy of the Plan, including, without limitation,
Section 9 thereof, and understands that this Stock Option is subject to the terms of the Plan and of this Agreement. This Agreement is hereby accepted, and the terms and conditions of the Plan, the Grant Notice and this Agreement, SPECIFICALLY
INCLUDING THE ARBITRATION PROVISIONS SET FORTH IN SECTION 7 OF THIS AGREEMENT, are hereby agreed to, by the undersigned as of the date first above written. 
  

			
	OPTIONEE:
	
	 
	Name:	 	
	
	 Address:

	 	 	 
		
	 	 	 
		
	 	 	 

  
 7 

 [SPOUSE’S CONSENT1 

I acknowledge that I have read the 
 foregoing Incentive Stock
Option Agreement 
 and understand the contents thereof. 

                          
                                         
     ] 
   

 

	1 	A spouse’s consent is recommended only if the Optionee’s state of residence is one of the following community property states: Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas, Washington and
Wisconsin. 

  
 8 

 
	
	DESIGNATED BENEFICIARY:
	
	 
	
	Beneficiary’s Address:
	
	   

	   

	 

  
 9 

 Appendix A 

STOCK OPTION EXERCISE NOTICE 
 Surface
Oncology, Inc. 
 Attention:
[                                         
   ] 
  
  

 
  

Pursuant to the terms of the grant notice and stock option agreement between the undersigned and Surface Oncology, Inc. (the
“Company”) dated __________ (the “Agreement”) under the Surface Oncology, Inc. 2014 Stock Option and Grant Plan, I, [Insert Name] ________________, hereby [Circle One] partially/fully exercise such option by
including herein payment in the amount of $             representing the purchase price for [Fill in number of Shares] _______ Shares. I have chosen the following form(s) of payment:

  

							
		 	[    ]	  	1.	  	Cash
		 	[    ]	  	2.	  	Certified or bank check payable to Surface Oncology, Inc.
		 	[    ]	  	3.	  	Other (as referenced in the Agreement and described in the Plan (please describe))
				
		 		  		  	                                      
                                         
                                         
                            .

 In connection with my exercise of the option as set forth above, I hereby represent and warrant to the Company
as follows: 
 (i) I am purchasing the Shares for my own account for investment only, and not for resale or with a view to
the distribution thereof. 
 (ii) I have had such an opportunity as I have deemed adequate to obtain from the Company such
information as is necessary to permit me to evaluate the merits and risks of my investment in the Company and have consulted with my own advisers with respect to my investment in the Company. 

(iii) I have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in
the purchase of the Shares and to make an informed investment decision with respect to such purchase. 
 (iv) I can afford a
complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period of time. 

(v) I understand that the Shares may not be registered under the Securities Act of 1933 (it being understood that the Shares
are being issued and sold in reliance on the exemption provided in Rule 701 thereunder) or any applicable state securities or “blue sky” laws and may not be sold or otherwise transferred or disposed of in the absence of an effective
registration statement under the Securities Act of 1933 and under any applicable state securities or “blue sky” laws (or exemptions from the registration requirement thereof). I further acknowledge that certificates representing Shares
will bear restrictive legends reflecting the foregoing and/or that book entries for uncertificated Shares will include similar restrictive notations. 

  
 10 

 (vi) I have read and understand the Plan and acknowledge and agree that the
Shares are subject to all of the relevant terms of the Plan, including without limitation, the transfer restrictions set forth in Section 9 of the Plan. 

(vii) I understand and agree that the Company has a right of first refusal with respect to the Shares pursuant to
Section 9(b) of the Plan. 
 (viii) I understand and agree that the Company has certain repurchase rights with respect
to the Shares pursuant to Section 9(c) of the Plan. 
 (ix) I understand and agree that I may not sell or otherwise
transfer or dispose of the Shares for a period of time following the effective date of a public offering by the Company as described in Section 9(f) of the Plan. 

 

			
	
	Sincerely yours,
	
	   

	Name:
	
	Address:
	
	 
	
	 
	
	 
		
	Date:	 	 

  
 11 

 NON-QUALIFIED STOCK OPTION GRANT NOTICE 

UNDER THE SURFACE ONCOLOGY, INC. 

2014 STOCK OPTION AND GRANT PLAN 

Pursuant to the Surface Oncology, Inc. 2014 Stock Option and Grant Plan (the “Plan”), Surface Oncology, Inc., a Delaware corporation
(together with any successor, the “Company”), has granted to the individual named below, an option (the “Stock Option”) to purchase on or prior to the Expiration Date, or such earlier date as is specified herein, all or any part
of the number of shares of Common Stock, par value $0.0001 per share (“Common Stock”), of the Company indicated below (the “Shares”), at the Option Exercise Price per share, subject to the terms and conditions set forth in this Non-Qualified Stock Option Grant Notice (the “Grant Notice”), the attached Non-Qualified Stock Option Agreement (the “Agreement”) and the Plan. This Stock
Option is not intended to qualify as an “incentive stock option” as defined in Section 422(b) of the Internal Revenue Code of 1986, as amended from time to time (the “Code”). 

 

			
	 Name of Optionee:
	  	                                 (the
“Optionee”)
		
	 No. of Shares:
	  	                     Shares of Common Stock
		
	 Grant Date:
	  	                                
		
	 Vesting Commencement Date:
	  	                                 (the “Vesting
Commencement Date”)
		
	 Expiration Date:
	  	                                 (the “Expiration
Date”)
		
	 Option Exercise Price/Share:
	  	$                               (the “Option Exercise
Price”)
		
	 Vesting Schedule:
	  	25 percent of the Shares shall vest and become exercisable on the first anniversary of the Vesting Commencement Date; provided that the Optionee continues to have a Service Relationship with the Company at such time. Thereafter,
the remaining 75 percent of the Shares shall vest and become exercisable in 36 equal monthly installments following the first anniversary of the Vesting Commencement Date, provided the Optionee continues to have a Service Relationship with the
Company on each vesting date. Notwithstanding anything in the Agreement to the contrary, in the case of a Sale Event, this Stock Option and the Shares shall be treated as provided in Section 3(c) of the Plan.

 Attachments: Non-Qualified Stock Option Agreement, 2014 Stock Option and Grant
Plan 

 NON-QUALIFIED STOCK OPTION AGREEMENT 

UNDER THE SURFACE ONCOLOGY, INC. 

2014 STOCK OPTION AND GRANT PLAN 

All capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Grant Notice and the Plan.

 1. Vesting, Exercisability and Termination. 

(a) No portion of this Stock Option may be exercised until such portion shall have vested and become exercisable. 

(b) Except as set forth below, and subject to the determination of the Committee in its sole discretion to accelerate the vesting schedule
hereunder, this Stock Option shall be vested and exercisable on the respective dates indicated below: 
 (i) This Stock
Option shall initially be unvested and unexercisable. 
 (ii) This Stock Option shall vest and become exercisable in
accordance with the Vesting Schedule set forth in the Grant Notice. 
 (c) Termination. Except as may otherwise be provided by the
Committee, if the Optionee’s Service Relationship is terminated, the period within which to exercise this Stock Option will be subject to earlier termination as set forth below (and if not exercised within such period, shall thereafter
terminate subject, in each case, to Section 3(c) of the Plan): 
 (i) Termination Due to Death or Disability. If
the Optionee’s Service Relationship terminates by reason of such Optionee’s death or Disability, this Stock Option may be exercised, to the extent exercisable on the date of such termination, by the Optionee, the Optionee’s legal
representative or legatee for a period of 12 months from the date of death or Disability or until the Expiration Date, if earlier. 

(ii) Other Termination. If the Optionee’s Service Relationship terminates for any reason other than death or
Disability, and unless otherwise determined by the Committee, this Stock Option may be exercised, to the extent exercisable on the date of termination, for a period of 90 days from the date of termination or until the Expiration Date, if earlier;
provided however, if the Optionee’s Service Relationship is terminated for Cause, this Stock Option shall terminate immediately upon the date of such termination. 

For purposes hereof, the Committee’s determination of the reason for termination of the Optionee’s Service Relationship shall be
conclusive and binding on the Optionee and his or her representatives or legatees and any Permitted Transferee. Any portion of this Stock Option that is not vested and exercisable on the date of termination of the Service Relationship shall
terminate immediately and be null and void. 

  
 2 

 2. Exercise of Stock Option. 

(a) The Optionee may exercise this Stock Option only in the following manner: Prior to the Expiration Date, the Optionee may deliver a Stock
Option exercise notice (an “Exercise Notice”) in the form of Appendix A hereto indicating his or her election to purchase some or all of the Shares with respect to which this Stock Option is then exercisable. Such
notice shall specify the number of Shares to be purchased. Payment of the purchase price may be made by one or more of the methods described in Section 5 of the Plan, subject to the limitations contained in such Section of the Plan, including
the requirement that the Committee specifically approve in advance certain payment methods. 
 (b) Notwithstanding any other provision
hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date. 
 3. Incorporation of Plan.
Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan. 

4. Transferability of Stock Option. This Stock Option is personal to the Optionee and is not transferable by the Optionee in any manner
other than by will or by the laws of descent and distribution. The Stock Option may be exercised during the Optionee’s lifetime only by the Optionee (or by the Optionee’s guardian or personal representative in the event of the
Optionee’s incapacity). The Optionee may elect to designate a beneficiary by providing written notice of the name of such beneficiary to the Company, and may revoke or change such designation at any time by filing written notice of revocation
or change with the Company; such beneficiary may exercise the Optionee’s Stock Option in the event of the Optionee’s death to the extent provided herein. If the Optionee does not designate a beneficiary, or if the designated beneficiary
predeceases the Optionee, the legal representative of the Optionee may exercise this Stock Option to the extent provided herein in the event of the Optionee’s death. 

5. Restrictions on Transfer of Shares. The Shares acquired upon exercise of the Stock Option shall be subject to certain transfer
restrictions and other limitations including, without limitation, the provisions contained in Section 9 of the Plan. 
 6.
Miscellaneous Provisions. 
 (a) Equitable Relief. The parties hereto agree and declare that legal remedies may be inadequate
to enforce the provisions of this Agreement and that equitable relief, including specific performance and injunctive relief, may be used to enforce the provisions of this Agreement. 

(b) Adjustments for Changes in Capital Structure. If, as a result of any reorganization, recapitalization, reincorporation,
reclassification, stock dividend, stock split, reverse stock split or other similar change in the Common Stock, the outstanding shares of Common Stock are increased or decreased or are exchanged for a different number or kind of securities of the
Company, the restrictions contained in this Agreement shall apply with equal force to additional and/or substitute securities, if any, received by the Optionee in exchange for, or by virtue of his or her ownership of, this Stock Option or Shares
acquired pursuant thereto. 

  
 3 

 (c) Change and Modifications. This Agreement may not be orally changed, modified or
terminated, nor shall any oral waiver of any of its terms be effective. This Agreement may be changed, modified or terminated only by an agreement in writing signed by the Company and the Optionee. 

(d) Governing Law. This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of
Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that would result
in the application of any law other than the law of the Commonwealth of Massachusetts. 
 (e) Headings. The headings are intended
only for convenience in finding the subject matter and do not constitute part of the text of this Agreement and shall not be considered in the interpretation of this Agreement. 

(f) Saving Clause. If any provision(s) of this Agreement shall be determined to be illegal or unenforceable, such determination shall
in no manner affect the legality or enforceability of any other provision hereof. 
 (g) Notices. All notices, requests, consents and
other communications shall be in writing and be deemed given when delivered personally, by telex or facsimile transmission or when received if mailed by first class registered or certified mail, postage prepaid. Notices to the Company or the
Optionee shall be addressed as set forth underneath their signatures below, or to such other address or addresses as may have been furnished by such party in writing to the other. 

(h) Benefit and Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, their
respective successors, assigns, and legal representatives. The Company has the right to assign this Agreement, and such assignee shall become entitled to all the rights of the Company hereunder to the extent of such assignment. 

(i) Counterparts. For the convenience of the parties and to facilitate execution, this Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same document. 
 (j)
Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. 

7. Dispute Resolution. 

(a) Except as provided below, any dispute arising out of or relating to the Plan or this Stock Option, this Agreement, or the breach,
termination or validity of the Plan, this Stock Option or this Agreement, shall be finally settled by binding arbitration conducted expeditiously in accordance with the J.A.M.S./Endispute Comprehensive Arbitration Rules and Procedures (the
“J.A.M.S. Rules”). The arbitration shall be governed by the United States Arbitration Act, 9 U.S.C. Sections 1-16, and judgment upon the award rendered by the arbitrators may be entered by any court
having jurisdiction thereof. The place of arbitration shall be Boston, Massachusetts. 

  
 4 

 (b) The arbitration shall commence within 60 days of the date on which a written demand for
arbitration is filed by any party hereto. In connection with the arbitration proceeding, the arbitrator shall have the power to order the production of documents by each party and any third-party witnesses. In addition, each party may take up to
three depositions as of right, and the arbitrator may in his or her discretion allow additional depositions upon good cause shown by the moving party. However, the arbitrator shall not have the power to order the answering of interrogatories or the
response to requests for admission. In connection with any arbitration, each party to the arbitration shall provide to the other, no later than seven business days before the date of the arbitration, the identity of all persons that may testify at
the arbitration and a copy of all documents that may be introduced at the arbitration or considered or used by a party’s witness or expert. The arbitrator’s decision and award shall be made and delivered within six months of the selection
of the arbitrator. The arbitrator’s decision shall set forth a reasoned basis for any award of damages or finding of liability. The arbitrator shall not have power to award damages in excess of actual compensatory damages and shall not multiply
actual damages or award punitive damages, and each party hereby irrevocably waives any claim to such damages. 
 (c) The Company, the
Optionee, each party to the Agreement and any other holder of Shares issued pursuant to this Agreement (each, a “Party”) covenants and agrees that such party will participate in the arbitration in good faith. This Section 7 applies
equally to requests for temporary, preliminary or permanent injunctive relief, except that in the case of temporary or preliminary injunctive relief any party may proceed in court without prior arbitration for the limited purpose of avoiding
immediate and irreparable harm. 
 (d) Each Party (i) hereby irrevocably submits to the jurisdiction of any United States District
Court of competent jurisdiction for the purpose of enforcing the award or decision in any such proceeding, (ii) hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any
claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution (except as protected by applicable law), that the suit, action or proceeding is brought in an
inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (iii) hereby waives and agrees not to seek any review by any court
of any other jurisdiction which may be called upon to grant an enforcement of the judgment of any such court. Each Party hereby consents to service of process by registered mail at the address to which notices are to be given. Each Party agrees that
its, his or her submission to jurisdiction and its, his or her consent to service of process by mail is made for the express benefit of each other Party. Final judgment against any Party in any such action, suit or proceeding may be enforced in
other jurisdictions by suit, action or proceeding on the judgment, or in any other manner provided by or pursuant to the laws of such other jurisdiction. 

[SIGNATURE PAGE FOLLOWS] 

  
 5 

 The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to
by the undersigned as of the date first above written. 
  

			
	SURFACE ONCOLOGY, INC.
		
	By:	 	 
		 	Name:
		 	Title:
	
	Address:
	
	 
	
	 
	
	 

 The undersigned hereby acknowledges receiving and reviewing a copy of the Plan, including, without limitation,
Section 9 thereof, and understands that this Stock Option is subject to the terms of the Plan and of this Agreement. This Agreement is hereby accepted, and the terms and conditions of the Plan, the Grant Notice and this Agreement, SPECIFICALLY
INCLUDING THE ARBITRATION PROVISIONS SET FORTH IN SECTION 7 OF THIS AGREEMENT, are hereby agreed to, by the undersigned as of the date first above written. 
  

	
	OPTIONEE:
	
	 
	Name:
	
	Address:
	
	 
	
	 
	
	 

  
 6 

 [SPOUSE’S CONSENT1 

I acknowledge that I have read the 
 foregoing Non-Qualified Stock Option Agreement 
 and understand the contents thereof. 

                          
                                         
     ] 
  
  

	1 	A spouse’s consent is recommended only if the Optionee’s state of residence is one of the following community property states: Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas, Washington and
Wisconsin. 

  
 7 

 
			
	DESIGNATED BENEFICIARY:
	
	 
	
	Beneficiary’s Address:
	
	 
	
	 
	
	 

  

  
 8 

 Appendix A 

STOCK OPTION EXERCISE NOTICE 
 Surface
Oncology, Inc. 
 Attention:
[                                    ] 

                          
                           

                          
                           

Pursuant to the terms of the grant notice and stock option agreement between the undersigned and Surface Oncology, Inc. (the “Company”) dated
                     (the “Agreement”) under the Surface Oncology, Inc. 2014 Stock Option and Grant Plan, I, [Insert
Name]                     , hereby [Circle One] partially/fully exercise such option by including herein payment in the amount of
$                     representing the purchase price for [Fill in number of Shares]
                     Shares. I have chosen the following form(s) of payment: 

 

							
		  	[    ]	  	1.	  	Cash
		  	[    ]	  	2.	  	Certified or bank check payable to Surface Oncology, Inc.
		  	[    ]	  	3.	  	Other (as referenced in the Agreement and described in the Plan (please describe))
		  		  		  	                                      
                                         
                                         
        .

 In connection with my exercise of the option as set forth above, I hereby represent and warrant to the Company
as follows: 
 (i) I am purchasing the Shares for my own account for investment only, and not for resale or with a view to
the distribution thereof. 
 (ii) I have had such an opportunity as I have deemed adequate to obtain from the Company such
information as is necessary to permit me to evaluate the merits and risks of my investment in the Company and have consulted with my own advisers with respect to my investment in the Company. 

(iii) I have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in
the purchase of the Shares and to make an informed investment decision with respect to such purchase. 
 (iv) I can afford a
complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period of time. 

(v) I understand that the Shares may not be registered under the Securities Act of 1933 (it being understood that the Shares
are being issued and sold in reliance on the exemption provided in Rule 701 thereunder) or any applicable state securities or “blue sky” laws and may not be sold or otherwise transferred or disposed of in the absence of an effective
registration statement under the Securities Act of 1933 and under any applicable state securities or “blue sky” laws (or exemptions from the registration requirement thereof). I further acknowledge that certificates representing Shares
will bear restrictive legends reflecting the foregoing and/or that book entries for uncertificated Shares will include similar restrictive notations. 

  
 9 

 (vi) I have read and understand the Plan and acknowledge and agree that the
Shares are subject to all of the relevant terms of the Plan, including without limitation, the transfer restrictions set forth in Section 9 of the Plan. 

(vii) I understand and agree that the Company has a right of first refusal with respect to the Shares pursuant to
Section 9(b) of the Plan. 
 (viii) I understand and agree that the Company has certain repurchase rights with respect
to the Shares pursuant to Section 9(c) of the Plan. 
 (ix) I understand and agree that I may not sell or otherwise
transfer or dispose of the Shares for a period of time following the effective date of a public offering by the Company as described in Section 9(f) of the Plan. 

 

			
	Sincerely yours,
	
	 
	Name:
	
	Address:
	
	 
	
	 
	
	 
		
	Date:	 	 

  
 10 

 RESTRICTED STOCK AWARD NOTICE 

UNDER THE SURFACE ONCOLOGY, INC. 

2014 STOCK OPTION AND GRANT PLAN 

Pursuant to the Surface Oncology, Inc. 2014 Stock Option and Grant Plan (the “Plan”), Surface Oncology, Inc., a Delaware corporation
(together with any successor, the “Company”), hereby grants, sells and issues to the individual named below, the Shares at the Per Share Purchase Price, subject to the terms and conditions set forth in this Restricted Stock Award Notice
(the “Award Notice”), the attached Restricted Stock Agreement (the “Agreement”) and the Plan. The Grantee agrees to the provisions set forth herein and acknowledges that each such provision is a material condition of the
Company’s agreement to issue and sell the Shares to him or her. The Company hereby acknowledges receipt of $[                ] in full payment for the
Shares. All references to share prices and amounts herein shall be equitably adjusted to reflect stock splits, stock dividends, recapitalizations, mergers, reorganizations and similar changes affecting the capital stock of the Company, and any
shares of capital stock of the Company received on or in respect of Shares in connection with any such event (including any shares of capital stock or any right, option or warrant to receive the same or any security convertible into or exchangeable
for any such shares or received upon conversion of any such shares) shall be subject to this Agreement on the same basis and extent at the relevant time as the Shares in respect of which they were issued, and shall be deemed Shares as if and to the
same extent they were issued at the date hereof. 
  

			
	Name of Grantee:	  	                                     (the
“Grantee”)
		
	No. of Shares:	  	                     Shares of Common Stock (the “Shares”)
		
	Grant Date:	  	                               ,
            
		
	Date of Purchase of Shares:	  	                               ,
            
		
	Vesting Commencement Date:	  	                               ,
             (the “Vesting Commencement Date”)
		
	Per Share Purchase Price:	  	$                 (the “Per Share Purchase Price”)
		
	Vesting Schedule:	  	25 percent of the Shares shall vest on the first anniversary of the Vesting Commencement Date; provided that the Grantee continues to have a Service Relationship with the Company at such time. Thereafter, the remaining
75 percent of the Shares shall vest in 36 equal monthly installments following the first anniversary of the Vesting Commencement Date, provided the Grantee continues to have a Service Relationship with the Company at such time. Notwithstanding
anything in the Agreement to the contrary in the case of a Sale Event, the Shares of Restricted Stock shall be treated as provided in Section 3(c) of the Plan.

 Attachments: Restricted Stock Agreement, 2014 Stock Option and Grant Plan 

 RESTRICTED STOCK AGREEMENT 

UNDER THE SURFACE ONCOLOGY, INC. 

2014 STOCK OPTION AND GRANT PLAN 

All capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Award Notice and the Plan.

 1. Purchase and Sale of Shares; Vesting; Investment Representations. 

(a) Purchase and Sale. The Company hereby sells to the Grantee, and the Grantee hereby purchases from the Company, the number of Shares
set forth in the Award Notice for the Per Share Purchase Price. 
 (b) Vesting. Initially, all of the Shares are non-transferable and subject to a substantial risk of forfeiture and are Shares of Restricted Stock. The risk of forfeiture shall lapse with respect to the Shares on the respective dates indicated on the Vesting
Schedule set forth in the Award Notice. 
 (c) Investment Representations. In connection with the purchase and sale of the Shares
contemplated by Section 1(a) above, the Grantee hereby represents and warrants to the Company as follows: 
 (i) The
Grantee is purchasing the Shares for the Grantee’s own account for investment only, and not for resale or with a view to the distribution thereof. 

(ii) The Grantee has had such an opportunity as he or she has deemed adequate to obtain from the Company such information as is
necessary to permit him or her to evaluate the merits and risks of the Grantee’s investment in the Company and has consulted with the Grantee’s own advisers with respect to the Grantee’s investment in the Company. 

(iii) The Grantee has sufficient experience in business, financial and investment matters to be able to evaluate the risks
involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase. 
 (iv) The
Grantee can afford a complete loss of the value of the Shares and is able to bear the economic risk of holding such Shares for an indefinite period. 

(v) The Grantee understands that the Shares are not registered under the Act (it being understood that the Shares are being
issued and sold in reliance on the exemption provided in Rule 701 thereunder) or any applicable state securities or “blue sky” laws and may not be sold or otherwise transferred or disposed of in the absence of an effective registration
statement under the Act and under any applicable state securities or “blue sky” laws (or exemptions from the registration requirements thereof). The Grantee further acknowledges that certificates representing the Shares will bear
restrictive legends reflecting the foregoing and/or that book entries for uncertificated Shares will include similar restrictive notations. 

  
 2 

 (vi) The Grantee has read and understands the Plan and acknowledges and agrees
that the Shares are subject to all of the relevant terms of the Plan, including without limitation, the transfer restrictions set forth in Section 9 of the Plan. 

(vii) The Grantee understands and agrees that the Company has a right of first refusal with respect to the Shares pursuant to
Section 9(b) of the Plan. 
 (viii) The Grantee understands and agree that the Company has certain repurchase rights
with respect to the Shares pursuant to Section 9(c) of the Plan. 
 (ix) The Grantee understands and agrees that the
Grantee may not sell or otherwise transfer or dispose of the Shares for a period of time following the effective date of a public offering by the Company as described in Section 9(f) of the Plan. 

2. Repurchase Right. Upon a Termination Event, the Company shall have the right to repurchase Shares of Restricted Stock that are
unvested as of the date of such Termination Event as set forth in Section 9(c) of the Plan. 
 3. Restrictions on Transfer of
Shares. The Shares (whether or not vested) shall be subject to certain transfer restrictions and other limitations including, without limitation, the provisions contained in Section 9 of the Plan 

4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Restricted Stock Award shall be subject to and governed
by all the terms and conditions of the Plan. 
 5. Miscellaneous Provisions. 

(a) Record Owner; Dividends. The Grantee and any Permitted Transferees, during the duration of this Agreement, shall be considered the
record owners of and shall be entitled to vote the Shares if and to the extent the Shares are entitled to voting rights. The Grantee and any Permitted Transferees shall be entitled to receive all dividends and any other distributions declared on the
Shares; provided, however, that the Company is under no duty to declare any such dividends or to make any such distribution. 

(b) Section 83(b) Election. The Grantee shall consult with the Grantee’s tax advisor to determine whether it would be appropriate
for the Grantee to make an election under Section 83(b) of the Code with respect to this Award. Any such election must be filed with the Internal Revenue Service within 30 days of the date of this Award. If the Grantee makes an election under
Section 83(b) of the Code, the Grantee shall give prompt notice to the Company (and provide a copy of such election to the Company). 

(c) Equitable Relief. The parties hereto agree and declare that legal remedies may be inadequate to enforce the provisions of this
Agreement and that equitable relief, including specific performance and injunctive relief, may be used to enforce the provisions of this Agreement. 

  
 3 

 (d) Change and Modifications. This Agreement may not be orally changed, modified or
terminated, nor shall any oral waiver of any of its terms be effective. This Agreement may be changed, modified or terminated only by an agreement in writing signed by the Company and the Grantee. 

(e) Governing Law. This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of
Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that would result
in the application of any law other than the law of the Commonwealth of Massachusetts. 
 (f) Headings. The headings are intended
only for convenience in finding the subject matter and do not constitute part of the text of this Agreement and shall not be considered in the interpretation of this Agreement. 

(g) Saving Clause. If any provision(s) of this Agreement shall be determined to be illegal or unenforceable, such determination shall
in no manner affect the legality or enforceability of any other provision hereof. 
 (h) Notices. All notices, requests, consents and
other communications shall be in writing and be deemed given when delivered personally, by telex or facsimile transmission or when received if mailed by first class registered or certified mail, postage prepaid. Notices to the Company or the Grantee
shall be addressed as set forth underneath their signatures below, or to such other address or addresses as may have been furnished by such party in writing to the other. 

(i) Benefit and Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, their
respective successors, assigns, and legal representatives. The Company has the right to assign this Agreement, and such assignee shall become entitled to all the rights of the Company hereunder to the extent of such assignment. 

(j) Counterparts. For the convenience of the parties and to facilitate execution, this Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same document. 
 (k)
Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. 

6. Dispute Resolution. 

(a) Except as provided below, any dispute arising out of or relating to the Plan or the Shares, this Agreement, or the breach, termination or
validity of the Plan, the Shares or this Agreement, shall be finally settled by binding arbitration conducted expeditiously in 

  
 4 

 
accordance with the J.A.M.S./Endispute Comprehensive Arbitration Rules and Procedures (the “J.A.M.S. Rules”). The arbitration shall be governed by the United States Arbitration Act, 9
U.S.C. Sections 1 - 16, and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof. The place of arbitration shall be Boston, Massachusetts. 

(b) The arbitration shall commence within 60 days of the date on which a written demand for arbitration is filed by any party hereto. In
connection with the arbitration proceeding, the arbitrator shall have the power to order the production of documents by each party and any third-party witnesses. In addition, each party may take up to three depositions as of right, and the
arbitrator may in his or her discretion allow additional depositions upon good cause shown by the moving party. However, the arbitrator shall not have the power to order the answering of interrogatories or the response to requests for admission. In
connection with any arbitration, each party to the arbitration shall provide to the other, no later than seven business days before the date of the arbitration, the identity of all persons that may testify at the arbitration and a copy of all
documents that may be introduced at the arbitration or considered or used by a party’s witness or expert. The arbitrator’s decision and award shall be made and delivered within six months of the selection of the arbitrator. The
arbitrator’s decision shall set forth a reasoned basis for any award of damages or finding of liability. The arbitrator shall not have power to award damages in excess of actual compensatory damages and shall not multiply actual damages or
award punitive damages, and each party hereby irrevocably waives any claim to such damages. 
 (c) The Company, the Grantee, each party to
the Agreement and any other holder of Shares issued pursuant to this Agreement (each, a “Party”) covenants and agrees that such party will participate in the arbitration in good faith. This Section 6 applies equally to requests for
temporary, preliminary or permanent injunctive relief, except that in the case of temporary or preliminary injunctive relief any party may proceed in court without prior arbitration for the limited purpose of avoiding immediate and irreparable harm.

 (d) Each Party (i) hereby irrevocably submits to the jurisdiction of any United States District Court of competent jurisdiction for
the purpose of enforcing the award or decision in any such proceeding, (ii) hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject
personally to the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution (except as protected by applicable law), that the suit, action or proceeding is brought in an inconvenient forum, that the
venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (iii) hereby waives and agrees not to seek any review by any court of any other jurisdiction
which may be called upon to grant an enforcement of the judgment of any such court. Each Party hereby consents to service of process by registered mail at the address to which notices are to be given. Each Party agrees that its, his or her
submission to jurisdiction and its, his or her consent to service of process by mail is made for the express benefit of each other Party. Final judgment against any Party in any such action, suit or proceeding may be enforced in other jurisdictions
by suit, action or proceeding on the judgment, or in any other manner provided by or pursuant to the laws of such other jurisdiction. 

[SIGNATURE PAGE FOLLOWS] 

  
 5 

 The foregoing Restricted Stock Agreement is hereby accepted and the terms and conditions thereof
are hereby agreed to by the undersigned as of the date of purchase of Shares above written. 
  

			
	SURFACE ONCOLOGY, INC.
		
	By:	 	 
		 	Name:
		 	Title:

  

			
	Address:	 	
	
	 
	
	 
	
	 

 The undersigned hereby acknowledges receiving and reviewing a copy of the Plan, including, without limitation,
Section 9 thereof and understands that the Shares granted hereby are subject to the terms of the Plan and of this Agreement. This Agreement is hereby accepted, and the terms and conditions of the Plan, the Award Notice and this Agreement,
SPECIFICALLY INCLUDING THE ARBITRATION PROVISIONS SET FORTH IN SECTION 6 OF THIS AGREEMENT, are hereby agreed to, by the undersigned as of the date first above written. 

 

			
	GRANTEE:
	
	 
	Name:
	
	Address:
	
	 
	
	 
	
	 

  
 6 

 [SPOUSE’S CONSENT1 

I acknowledge that I have read the 
 foregoing Restricted Stock
Agreement 
 and understand the contents thereof. 

                          
                                         
             ] 
  

 

	1 	A spouse’s consent is required only if the Grantee’s state of residence is one of the following community property states: Arizona, California, Idaho, Louisiana, New Mexico, Nevada, Texas, Washington and
Wisconsin. 

  
 7EX-10.13

 Exhibit 10.13 

EXECUTION VERSION 
 EMPLOYMENT
AGREEMENT 
 THIS EMPLOYMENT AGREEMENT (this “Agreement”), made this 23rd
day of November, 2016 is entered into by Surface Oncology, Inc., a Delaware corporation (the “Company”), and Daniel S. Lynch, an individual residing at 18 Marlborough St, Boston, MA 02116 (the “Executive”). 

INTRODUCTION 
 The Company
and the Executive desire to establish the terms and conditions of the Executive’s employment with the Company. In consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged by the parties hereto, the parties agree as follows: 
 1. Services. The Executive agrees
to be employed by the Company, serving in a senior management role and performing such duties as may be reasonably requested from time to time by the Company, such duties to be performed at such times and places as shall be mutually agreed to by the
Company and the Executive. The Executive shall dedicate twenty percent (20%) of his professional time to the Company. The Company agrees to cause the Executive to be elected to the Board of Directors of the Company (the “Board”) as
Executive Chairman and Chairman of the Board, and Executive agrees to serve in such capacities. The Executive shall serve on the Board until such time as this Agreement shall terminate pursuant to Section 4 herein, at which
time the Executive shall resign from the Board and from all positions as an officer or director of the Company, unless the Board of Directors of the Company determines, in its sole discretion, to have the Executive continue to serve as a member of
the Board notwithstanding termination of this Agreement. 
 2. Term. This Agreement shall commence on the date hereof and shall
continue until the Executive’s employment with the Company is terminated in accordance with the provisions of Section 4, whereupon this Agreement shall terminate (such period, the “Employment Period”). 

3. Compensation. 
 3.1
Salary/Bonus. During the Employment Period, the Company shall pay to the Executive a salary of $12,500 per month ($150,000 on an annual basis (the “Base Compensation”)), payable in accordance with the Company’s normal payroll
practices for its executives. Payment for any partial month during the Employment Period shall be prorated. In addition, the Executive will be eligible to receive an annual performance bonus of up to twenty-five percent (25%) of the Base
Compensation, as determined by the Board using for such determination the same method used by the Board in determining the annual performance bonus of the Company’s Chief Executive Officer. Each annual performance bonus, if earned, shall be
paid to the Executive no later than March 15th of the calendar year immediately following the calendar year for which such bonus was earned. The Executive must be an employee of the Company on
September 30th of the applicable bonus year to earn any part of that bonus and, in the event that the Executive is not an employee of the Company through the last day of the applicable bonus year,
the amount of such bonus shall be pro-rated based on the number of days in such bonus year that the Executive was employed by the Company. 

 3.2 Equity. 

(a) Initial Equity Grant. As soon as practicable after entering into this Agreement, the Company shall grant the Executive an stock
option which, to the extent permitted by law, shall be an incentive stock option (the “Initial Option”) under the Company’s 2014 Stock Option and Incentive Plan (the “Plan”) for the purchase of 743,368 shares of common stock
of the Company (the “Initial Shares”) at a per share purchase price equal to the fair market value, as determined by the Board, on the date of the grant. The Company hereby represents and warrants that the Initial Shares represent a one
and one half percent (1.5%) ownership interest in the Company as of the date hereof (based on the number of shares of common stock of the Company outstanding, assuming the exercise of all outstanding options, warrants and other rights to purchase
capital stock of the Company and the conversion of all securities convertible into common stock of the Company). Subject to the acceleration provisions set forth in Sections 3.2(c) and 3.5, the Initial Option will vest, starting on the date hereof
(the “Vesting Commencement Date”), at the rate of 2.0833% for each consecutive month that the Executive continues to be employed by the Company until the date that is four (4) full years after the Vesting Commencement Date, at which
time the Initial Option will be fully vested. 
 (b) Additional Equity Grants. In addition, for so long as the Executive continues
to be employed by the Company, subject to the determination of the Board and the Executive’s performance of his obligations hereunder, the Company shall from time to time, including, but not limited to, at such times as the Company considers
the grant of equity awards to any of the Company’s senior executives, consider the grant to the Executive of additional stock options (the “Additional Options”) for the purchase of additional shares of common stock of the Company (the
“Additional Shares”). 
 (c) Acceleration Upon a Sale. Notwithstanding the vesting schedules of the Initial Option and any
Additional Options, upon a Deemed Liquidation Event (as defined in the Company’s amended and restated certificate of incorporation, provided in no event shall an IPO, a financing event that does not result in the distribution of proceeds to the
Company’s stockholders or a wind-down be a Deemed Liquidation Event for purposes of this Agreement), of the Company, the vesting schedule of the Initial Option and any Additional Options shall be accelerated in full and the Initial Option and
any Additional Options shall be immediately exercisable for the purchase of all or any portion of the full number of Initial Shares and the full number of Additional Shares. 

3.3 Expenses. The Company shall reimburse the Executive for all reasonable documented out of pocket expenses incurred or paid by the
Executive in connection with, or related to, the performance of his duties under this Agreement, including Executive’s travel and lodging expenses and Executive’s administrative support expenses; provided, however, (x) for such
expenses as may also be reasonably related to the Executive’s performance of services for a third party, the Company shall only be obligated to reimburse the Executive for such expenses in an amount based on the Executive’s pro rata time
commitments to the Company as compared to 

  
 - 2 - 

 
any third parties in connection with such expense and (y) the maximum amount of the Executive’s administrative support expenses that the Company shall be required to reimburse shall be
$5,000 per year. The Executive shall submit to the Company documentation, expense statements and other supporting evidence as the Company may reasonably request from the Executive and an itemized monthly statement of such expenses incurred in the
previous month. The Company shall pay to the Executive amounts shown on each such statement within thirty (30) days after receipt thereof. The Company shall pay the reasonable and documented fees and expenses of Wilmer Cutler Pickering Hale and
Dorr LLP, counsel for the Executive, incurred in connection with the preparation and negotiation of this Agreement, not to exceed $7,500. All reimbursements provided under this Agreement shall be made in accordance with the requirements of
Section 409A (“Section 409A”) of the Internal Revenue Code of 1986 and any successor statute, regulation and guidance thereto (the “Code”), including, where applicable, the requirement that: (i) any reimbursement
is for expenses incurred during the Executive’s lifetime (or during a shorter period of time specified in this Agreement); (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for
reimbursement in any other calendar year; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred; and (iv) the right to reimbursement
or in kind benefits is not subject to liquidation or exchange for another benefit. 
 3.4 Benefits. The Executive and the members of
his immediate family shall be entitled to participate in all health and dental benefit programs that the Company establishes and makes available to its employees, and all other benefit programs that the Company establishes and makes available to its
employees, if any, each in case to the extent that Executive’s position, tenure, salary, age, health and other qualifications make him eligible to participate, subject to the terms of such plans. In the event that (x) the Executive is not
eligible to participate in all health benefit programs that the Company establishes and makes available to its employees and (y) the Executive does not have comparable coverage under a plan or plans of other employers, the Company shall pay to
the Executive a monthly cash payment in an amount equal to twenty percent (20%) of the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive was a full-time employee and eligible
to participate in such health benefit program. 
 3.5 Severance and Vesting Acceleration. 

(a) In the event that (i) the Company terminates the Executive’s employment hereunder without Cause (as defined below) or
(ii) the Executive terminates his employment hereunder for Good Reason (as defined below), if the Executive enters into a valid and irrevocable release of all claims against the Company and all related persons and entities in the form
substantially similar to the form attached hereto as Exhibit A (the “Release”) and such Release becomes irrevocable within 60 days following the termination of the Executive’s employment hereunder, then upon the Effective Date
(as defined in the Release) (or if later, upon the date of the Executive’s “separation from service” as defined in Section 409A of the Code), and Executive complies with his continuing obligations pursuant to Section 6, (x)
the Executive shall be entitled to the salary that would have been payable to the Executive pursuant to Section 3.1 during the Post Termination Period, and (y) the portion of the Initial Option and any Additional Options that would have
vested during the Post Termination Period if this Agreement was not so terminated shall immediately vest. 

  
 - 3 - 

 (b) For purposes of this Agreement, “Post Termination Period” shall mean a period
immediately following the effective date of the termination of this Agreement of twelve (12) successive months. 
 (c) For purposes of
this Agreement, “Cause” means: (i) that (x) the Executive has willfully and intentionally failed to substantially perform his reasonably assigned duties for the Company, as reasonably assigned by the Board or its designee, or to
follow the applicable material policies or procedures of the Company in effect from time to time and such non-performance, failure or breach continues for a period of ten (10) business days following
written notice by the Company to the Executive of such failure, (y) the Executive has engaged in an act of material dishonesty, fraud or willful misconduct in connection with the Executive’s duties hereunder or in dealings with the Company
or knowing engagement in conduct which reasonably would be expected to be materially detrimental or injurious (monetarily or otherwise) to the Company, or (z) the Executive’s breach of any material provision of this Agreement or any other
agreement by and between the Executive and the Company, which breach is not cured within ten (10) business days following written notice by the Company to the Executive of such breach; or (ii) the conviction of the Executive of, or the
entry of a pleading of guilty or nolo contendere by the Executive to, any felony, other than automobile violations. 
 (d) For purposes of
this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason Process” (hereinafter defined) following the occurrence of any of the following events: (i) reduction of Executive’s base
salary without Executive’s prior written consent; (ii) material diminution in Executive’s duties, responsibilities and authorities with the Company, without Executive’s prior written consent; (iii) relocation of the
Company’s offices more than 50 miles away from the current location without Executive’s prior written consent; or (iv) any material breach by the Company or any successor thereto of this Agreement. “Good Reason Process”
shall mean that (i) Executive has reasonably determined in good faith that a “Good Reason” condition has occurred; (ii) Executive has notified the Company in writing of the first occurrence of the Good Reason condition within 90
days of the first occurrence of such condition; (iii) Executive has cooperated in good faith with the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”), to remedy the condition;
(iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) Executive terminates Executive’s employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition
during the Cure Period, Good Reason shall be deemed not to have occurred. 
 3.6 Withholding. All salary, bonus and other
compensation payable to the Executive shall be subject to applicable withholding taxes. 
 4. Termination. The Executive’s
employment under this Agreement may be terminated by either the Company or the Executive upon written notice to the other party provided, however, the Executive may terminate the Executive’s employment under this Agreement for Good Reason, in
accordance with the notice provisions provided under Section 3.5(d). In the event of any termination of this Agreement, the Executive shall be entitled to 

  
 - 4 - 

 
payment hereunder and for expenses paid or incurred prior to the effective date of termination. For the avoidance of doubt, if (i) the Company terminates the Executive’s service for
Cause, or (ii) the Executive terminates his service for any reason (except for Good Reason), then in each case the Executive shall not be entitled to any severance or accelerated vesting as set forth in Section 3.5. 

5. Cooperation. The Company shall provide such access to its information and property as may be reasonably required in order to permit
the Executive to perform his obligations hereunder. The Executive shall cooperate with the Company’s personnel, shall not interfere with the conduct of the Company’s business and shall observe all rules, regulations and security
requirements of the Company concerning the safety of persons and property. 
 6. Proprietary Information and Inventions. 

6.1 Proprietary Information. 

(a) The Executive acknowledges that his relationship with the Company is one of high trust and confidence and that in the course of his
employment with the Company he will have access to and contact with Proprietary Information. The Executive shall not disclose any Proprietary Information to any person or entity other than employees, officers, directors, lawyers, accountants and
consultants of the Company or use the same for any purposes (other than in the performance of his duties as an employee or director of the Company) without written approval by an officer of the Company, either during or after the Employment Period,
unless and until such Proprietary Information has become public knowledge without fault by the Executive. 
 (b) For purposes of this
Agreement, Proprietary Information shall mean, by way of illustration and not limitation, all information, whether or not in writing, whether or not patentable and whether or not copyrightable, of a private, secret or confidential nature, owned,
possessed or used by the Company, concerning the Company’s business, business relationships or financial affairs, including, without limitation, any Invention, formula, vendor information, customer information, apparatus, equipment, trade
secret, process, research, report, technical or research data, clinical data, know-how, computer program, software, software documentation, hardware design, technology, product, processes, methods, techniques,
formulas, compounds, projects, developments, marketing or business plan, forecast, unpublished financial statement, budget, license, price, cost, customer, supplier or personnel information or employee list that is communicated to, learned of,
developed or otherwise acquired by the Executive in the course of performing his duties as an employee of the Company. 
 (c) The
Executive’s obligations under this Section 6.1 shall not apply to any information that (i) is or becomes known to the general public under circumstances involving no breach by the Executive or others of the terms of this
Section 6.1, (ii) is generally disclosed to third parties by the Company without restriction on such third parties, or (iii) is approved for release by written authorization of an officer of the Company. 

  
 - 5 - 

 (d) The Executive agrees that all files, documents, letters, memoranda, reports, records, data
sketches, drawings, models, laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible material containing Proprietary Information, whether created by the Executive or
others, which shall come into his custody or possession, shall be and are the exclusive property of the Company to be used by the Executive only in the performance of his duties for the Company and shall not be copied or removed from the Company
premises except in the pursuit of the business of the Company. All such materials or copies thereof and all tangible property of the Company in the custody or possession of the Executive shall be delivered to the Company, upon the earlier of
(i) a request by the Company or (ii) the termination of this Agreement. After such delivery, the Executive shall not retain any such materials or copies thereof or any such tangible property. 

(e) The Executive agrees that his obligation not to disclose or to use information and materials of the types set forth in paragraphs
(b) and (d) above, and his obligation to return materials and tangible property set forth in paragraph (d) above extends to such types of information, materials and tangible property of customers of the Company or suppliers to the Company
or other third parties who may have disclosed or entrusted the same to the Company or to the Executive. 
 (f) The Executive acknowledges
that the Company from time to time may have agreements with other persons or with the United States Government, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the course of work under
such agreements or regarding the confidential nature of such work. The Executive agrees to be bound by all such obligations and restrictions that are known to him and to take all action necessary to discharge the obligations of the Company under
such agreements. 
 (g) Pursuant to the federal Defend Trade Secrets Act of 2016, Executive shall not be held criminally or civilly liable
under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely
for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Further, nothing in this Agreement shall be
interpreted or applied to prohibit Executive from making any good faith report to any governmental agency or other governmental entity concerning any acts or omissions that Executive believes to constitute a possible violation of federal or state
law or making other disclosures that are protected under the whistleblower provisions of applicable federal or state law or regulation. 

6.2 Inventions. 
 (a)
All inventions, creations, discoveries, computer programs, data, developments, technology, designs, innovations and improvements (whether or not patentable and whether or not copyrightable) which are made, conceived, reduced to practice, created,
written, designed or developed by the Executive, solely or jointly with others or under his direction and whether during normal business hours or otherwise, (i) during the Employment Period if made, conceived, reduced to practice, created,
written, designed or developed in the course of Executive’s performance of duties pursuant to this Agreement or (ii) during or after the Employment Period if resulting or directly derived from Proprietary Information (collectively

  
 - 6 - 

 
under clauses (i) and (ii), “Inventions”), shall be the sole property of the Company. The Executive hereby assigns and transfers and, to the extent any such assignment cannot be
made at present, will assign and transfer, to the Company all Inventions and any and all related patents, copyrights, trademarks, trade names, and other industrial and intellectual property rights and applications therefor, in the United States and
elsewhere and appoints any officer of the Company as his duly authorized attorney to execute, file, prosecute and protect the same before any government agency, court or authority. However, this paragraph shall not apply to Inventions which do
not relate to the business or research and development conducted or planned to be conducted by the Company at the time such Invention is created, made, conceived or reduced to practice and which are made and conceived by the Executive not during
normal working hours, not on the Company’s premises and not using the Company’s tools, devices, equipment or Proprietary Information. 

(b) Upon the request of the Company and at the Company’s expense, the Executive shall execute such further assignments, documents and
other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other rights in the United States and in any
foreign country with respect to any Invention. The Executive also hereby waives all claims to moral rights in any Inventions. 
 (c) The
Executive shall promptly disclose to the Company all Inventions and shall maintain adequate and current written records (in the form of notes, sketches, drawings and as may be specified by the Company) to document the conception and/or first actual
reduction to practice of any Invention. Such written records shall be available to and remain the sole property of the Company at all times. 

6.3 Non-Competition and Non-Solicitation. 

(a) In order to protect the Company’s confidential information, Inventions and good will, during the Employment Period and for a period
of one (1) year following the termination of the Executive’s employment for any reason (the “Restricted Period”), the Executive will not directly or indirectly, whether as owner, partner, shareholder, director, manager,
consultant, agent, employee, co-venturer or otherwise, engage or participate in any business activity (“Activities”) anywhere in the United States that develops, manufactures or markets any products
that are directed to the same molecular targets as any products that are under development or that are the subject of active planning at any time during the Executive’s employment with the Company (“Field”); provided that this shall
not prohibit any possible investment in publicly traded stock of a company representing less than one percent of the stock of such company. Notwithstanding the immediately preceding sentence, if (x) after the time the Executive begins
performing Activities for a third party, the Executive learns that such third party is engaged in the development, manufacture or marketing of one or more products in the Field and (y) the Executive is permitted by such third party to disclose
the third party’s identity and the specific molecular target of such product or products to the Company, the Executive shall promptly thereafter disclose the identity of such third party and such specific molecular target. Alternatively, if the
Executive is not permitted by such third party to disclose the identity of such third party or the specific molecular target of such product or products to the Company, the Executive shall promptly notify the Company that he is engaged in Activities
for a third party 

  
 - 7 - 

 
engaged in the development, manufacture or marketing of one or more products in the Field (without disclosing the Third Party’s identity or the specific molecular target of such product or
products). In either such case, the Company may as a result of such disclosure elect to terminate this Agreement pursuant to Section 4, such termination by the Company to be deemed to have been made without Cause. For the
avoidance of doubt, this Section 6.3 shall not prevent the Executive’s employment by a business entity that develops, manufactures or markets any products that are directed to the same molecular targets as any products that are under
development or that are the subject of active planning at any time during the Employment Period, provided that the Executive does not engage or participate in any business activity that directly supports such development, manufacture or marketing.

 (b) In addition, during the Restricted Period, the Executive will not, directly or indirectly, in any manner, other than for the benefit
of the Company, (a) call upon, solicit, divert, take away, accept or conduct any business from or with any of the customers or prospective customers of the Company or any of its suppliers, and/or (b) unless the Company consents in writing
(such consent not be unreasonably withheld), solicit, entice, attempt to persuade any other employee or consultant of the Company to leave the Company for any reason or otherwise participate in or facilitate the hire, directly or through another
entity, of any person who is employed or engaged by the Company or who was employed or engaged by the Company within six months of any attempt to hire such person. The Executive acknowledges and agrees that if he violates any of the provisions of
this paragraph 6.3, the running of the Restricted Period will be extended by the time during which the Executive engages in such violation(s). 

7. Other Agreements. The Executive represents that his performance of all the terms of this Agreement and the performance of his duties
as an employee of the Company do not and will not breach any agreement with any third party to which the Executive is a party (including, without limitation, any nondisclosure or non-competition agreement),
and that the Executive will not disclose to the Company or induce the Company to use any trade secrets, confidential or proprietary information or material belonging to any current or previous employer or others. 

8. Non-Exclusivity. Except as set forth in Section 6.3, the Executive retains the right to
be employed by other companies and to contract with other companies or entities for his consulting services without restriction. 
 9.
Remedies. The Executive acknowledges that any breach of the provisions of Section 6 of this Agreement shall result in serious and irreparable injury to the Company for which the Company cannot be adequately compensated by monetary
damages alone. The Executive agrees, therefore, that, in addition to any other remedy it may have, the Company shall be entitled to enforce the specific performance of this Agreement by the Executive and to seek both temporary and permanent
injunctive relief (to the extent permitted by law) without the necessity of proving actual damages or posting a bond. 
 10. Notices.
All notices required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal delivery or three days after deposit in the United States Post Office, by registered or certified mail (return receipt requested),
postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses as either party shall designate to the other in accordance with this Section 10. 

  
 - 8 - 

 11. Pronouns. Whenever the context may require, any pronouns used in this Agreement shall
include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 

12. Entire Agreement. This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and
understandings, whether written or oral, relating to the subject matter of this Agreement. 
 13. Amendment. This Agreement may be
amended or modified only by a written instrument executed by both the Company and the Executive. 
 14.
Non-Assignability of Contract. This Agreement is personal to the Executive and the Executive shall not have the right to assign any of his rights or delegate any of his duties without the express
written consent of the Company. Any non-consented-to assignment or delegation, whether express or implied or by operation of law, shall be void and shall constitute a
breach and a default by the Executive. 
 15. Governing Law. This Agreement shall be governed by and construed in accordance with the
laws of the Commonwealth of Massachusetts without giving effect to any choice or conflict of law provision or rule that would cause the application of laws of any other jurisdiction. 

16. Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective
successors and assigns, including any entity with which, or into which, the Company may be merged or consolidated or which may succeed to its assets or business, provided, however, that the obligations of the Executive are personal and shall not be
assigned by him. 
 17. Interpretation. If any restriction set forth in Section 6 is found by any court of competent
jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities
or geographic area as to which it may be enforceable. 
 18. Survival. Section 3.5 and Sections 4 through 20 shall survive the
expiration or termination of this Agreement. 
 19. Section 409A. 

19.1 To the extent that any payment or benefit described in this Agreement constitutes
“non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of service, then such
payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation Section 1.409A-1(h). 

  
 - 9 - 

 19.2 The parties intend that this Agreement will be administered in accordance with
Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with
Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this
Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder
without additional cost to either party. 
 19.3 The Company makes no representation or warranty and shall have no liability to the
Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

20. Miscellaneous. 
 20.1
No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. No waiver of any term or condition of this Agreement shall be valid or binding on either Party unless the same
shall be been mutually assented to in writing by both Parties. The failure of either Party to enforce at any time any of the provisions of this Agreement, or the failure to require at any time performance by the other Party of any of the provisions
of this Agreement, shall in no way be construed to be a present or future waiver of such provisions, nor in any way affect the right of either Party to enforce each and every such provision thereafter. The express waiver by either Party of any
provision, condition or requirement of this Agreement shall not constitute a waiver of any future obligation to comply with such provision, condition or requirement. 

20.2 The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or
substance of any section of this Agreement. 
 20.3 In the event that any provision of this Agreement shall be invalid, illegal or otherwise
unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

[Remainder of Page Intentionally Left Blank] 

  
 - 10 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set
forth above. 
  

			
	SURFACE ONCOLOGY, INC.
		
	By:	 	/s/ Detlev Biniszkiewicz
	Name: Detlev Biniszkiewicz
	Title: President and CEO

  

	
	EXECUTIVE
	
	/s/ Daniel Lynch
	Daniel S. Lynch

 Signature Page to Employment Agreement 

 Exhibit A 

SEPARATION AGREEMENT AND RELEASE 

This Separation Agreement and Release (“Agreement”) is made by and between Daniel S. Lynch (“Executive”) and
Surface Oncology, Inc. (the “Company”) (collectively, referred to as the “Parties” or individually referred to as a “Party”). 

WHEREAS, the Parties have previously entered into that certain Employment Agreement, dated as of November [__], 2016 (the “Employment
Agreement”); and 
 WHEREAS, in connection with the termination of the Employment Agreement, the Parties wish to resolve any and
all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that the Executive may have against the Company and any of the Releasees (as defined below) arising out of or related to the Executive’s provision of
services to or termination of employment with the Company or its subsidiaries or affiliates or the termination of the Employment Agreement (the “Employment Relationship”) but, for the avoidance of doubt, nothing herein will be
deemed to release any rights or remedies in connection with amounts owed to, or vested benefits for, the Executive (or his immediate family members) under Sections 3.1, 3.3 and 3.4 of the Employment Agreement through the effective date of
termination thereof, the Executive’s ownership of vested equity securities of the Company, the Executive’s right to indemnification by the Company or any of its affiliates pursuant to contract or applicable law or Directors’ and
Officers’ insurance, or the Executive’s rights to payments under this Agreement (collectively, the “Retained Claims”). 

NOW, THEREFORE, in consideration of the payment to the Executive of the compensation and benefits described in Section 3.5(a) of the
Employment Agreement (the “Termination Payments”), which, pursuant to the Employment Agreement, are conditioned on the Executive’s execution and non-revocation of this Agreement, and in
consideration of the mutual promises made herein, the Company and the Executive hereby agree as follows: 
 1. Severance Payments. The
Company agrees to provide the Executive with the Termination Payments, payable at the times set forth in, and subject to the terms and conditions of, the Employment Agreement. 

2. Release of Claims. The Executive agrees that, other than with respect to the Retained Claims, the foregoing consideration represents
settlement in full of all outstanding obligations owed to the Executive by the Company, any of its direct or indirect subsidiaries and affiliates, and any of its or their current and former officers, directors, equity holders, managers, employees,
agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor and successor corporations and assigns (collectively, the
“Releasees”) arising out of or related to the Employment Relationship and any prior employment relationship. The Executive, on his own behalf and on behalf of the Executive’s heirs, family members, executors, agents, successors
and assigns, other than with respect to the Retained Claims, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, or
cause of action relating to any matters 

  
 A-1 

 
of any kind, whether presently known or unknown, suspected or unsuspected, that the Executive may possess against any of the Releasees arising from any omissions, acts, facts, or damages that
have occurred up until and including the Effective Date of this Agreement (as defined in Section 7 below) and arising out of or related to the Employment Relationship and any prior employment relationship between the
Company and the Executive, including, without limitation, to the extent arising out of or related to the Employment Relationship or any such prior employment relationship: 

(a) any and all claims relating to, or arising from, the Executive’s right to purchase, or actual purchase of any shares
of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud
under any state or federal law; 
 (b) any and all claims for wrongful dismissal or discharge of employment; termination in
violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction
of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury;
assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits; 
 (c) any and all claims for
violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay
Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act; the Family
and Medical Leave Act; the Sarbanes-Oxley Act of 2002; the Massachusetts Fair Employment Practices Act; the Massachusetts Civil Rights Act; the Massachusetts Equal Rights Act; the Massachusetts Labor and Industries Act; the Massachusetts Privacy
Act; and the Massachusetts Maternity Leave Act, all as amended; 
 (d) any and all claims for violation of the federal or any
state constitution; 
 (e) any and all claims arising out of any other laws and regulations relating to employment, the
provision of consulting services or employment discrimination; 
 (f) any claim for any loss, cost, damage, or expense
arising out of any dispute over the non-withholding or other tax treatment of any of the proceeds received by the Executive as a result of this Agreement; and 

(g) any and all claims for compensatory damages, punitive damages, injunctive relief, attorneys’ fees and costs. 

  
 A-2 

 The Executive agrees that the release set forth in this section shall be and remain in effect in all respects as
a complete general release as to the matters released. This release does not release claims that cannot be released as a matter of law, including, but not limited to, the Executive’s right to file a charge with or participate in a charge by the
Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment or consulting service, against the Company (with the
understanding that the Executive’s release of claims herein bars the Executive from recovering monetary relief from the Company or any Releasee), claims for unemployment compensation or any state disability insurance benefits pursuant to the
terms of applicable state law, claims to continued participation in certain of the Company’s group benefit plans pursuant to the terms and conditions of COBRA, claims to any benefit entitlements vested as of the date of termination of the
Employment Relationship, pursuant to the written terms of any benefit plan of the Company or its affiliates and the Executive’s rights under applicable law, and any Retained Claims. 

3. Acknowledgment of Waiver of Claims under ADEA. The Executive understands and acknowledges that the Executive is waiving and
releasing any rights the Executive may have under the Age Discrimination in Employment Act of 1967 (“ADEA”), and that this waiver and release is knowing and voluntary. The Executive understands and agrees that this waiver and
release does not apply to any rights or claims that may arise under the ADEA after the Effective Date of this Agreement. The Executive understands and acknowledges that the consideration given for this waiver and release is in addition to anything
of value to which the Executive was already entitled. The Executive further understands and acknowledges that the Executive has been advised by this writing that: (a) the Executive should consult with an attorney prior to executing this
Agreement; (b) the Executive has 21 days within which to consider this Agreement; (c) the Executive has 7 days following the Executive’s execution of this Agreement to revoke this Agreement pursuant to written notice to the Secretary
of the Company; (d) this Agreement shall not be effective until after the revocation period has expired; and (e) nothing in this Agreement prevents or precludes the Executive from challenging or seeking a determination in good faith of the
validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event the Executive signs this Agreement and returns it to the Company in
less than the 21 day period identified above, the Executive hereby acknowledges that the Executive has freely and voluntarily chosen to waive the time period allotted for considering this Agreement. 

4. Severability. In the event that any provision or any portion of any provision hereof or any surviving agreement made a part hereof
becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision or portion of provision. 

5. No Oral Modification. This Agreement may only be amended in a writing signed by the Executive and a duly authorized officer of the
Company. 
 6. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of
Massachusetts without giving effect to any choice or conflict of law provision or rule that would cause the application of laws of any other jurisdiction. 

  
 A-3 

 7. Effective Date. If the Executive has attained or is over the age of 40 as of the date
of the Executive’s termination of services, then the Executive has seven days after the Executive signs this Agreement to revoke it and this Agreement will become effective on the eighth day after the Executive signed this Agreement, so long as
it has been signed by the Parties and has not been revoked by either Party before that date (the “Effective Date”). If the Executive has not attained the age of 40 as of the date of the Executive’s termination of services, then
the “Effective Date” shall be the date on which the Executive signs this Agreement. 
 8. Voluntary Execution of Agreement.
The Executive understands and agrees that the Executive executed this Agreement voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of the Executive’s
claims as set forth above against the Company and any of the other Releasees arising out of or related to the Employment Relationship and any prior employment relationship. The Executive acknowledges that: (a) the Executive has read this
Agreement; (b) the Executive has not relied upon any representations or statements made by the Company that are not specifically set forth in this Agreement; (c) the Executive has been represented in the preparation, negotiation, and
execution of this Agreement by legal counsel of the Executive’s own choice or has elected not to retain legal counsel; (d) the Executive understands the terms and consequences of this Agreement and of the releases it contains; and
(e) the Executive is fully aware of the legal and binding effect of this Agreement. 
 [Signature Page Follows] 

  
 A-4 

 IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set forth
below. 
  

							
		 		 		 	EXECUTIVE
				
	Dated:
                                         
   	 		 		 	                                      
                                         
        
				
		 		 		 	Daniel S. Lynch
				
		 		 		 	
		 		 		 	COMPANY
		 		 		 	
		 		 		 	SURFACE ONCOLOGY, INC.
		 		 		 	
	Dated:
                                         
   	 		 		 	By:                                     
                                         
     
		 		 		 	Name:                                     
                                         

		 		 		 	Title:                                     
                                         
  

  
 A-5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]